NZ621515B2 - Method for inhibiting cellular activation by insulin-like growth factor-1 - Google Patents
Method for inhibiting cellular activation by insulin-like growth factor-1 Download PDFInfo
- Publication number
- NZ621515B2 NZ621515B2 NZ621515A NZ62151512A NZ621515B2 NZ 621515 B2 NZ621515 B2 NZ 621515B2 NZ 621515 A NZ621515 A NZ 621515A NZ 62151512 A NZ62151512 A NZ 62151512A NZ 621515 B2 NZ621515 B2 NZ 621515B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- iap
- shps
- igf
- cells
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 32
- 230000004913 activation Effects 0.000 title description 20
- 230000001413 cellular Effects 0.000 title description 9
- 102100014231 IGF1 Human genes 0.000 title description 7
- 101700074337 IGF1 Proteins 0.000 title description 7
- 102000004965 antibodies Human genes 0.000 claims abstract description 194
- 108090001123 antibodies Proteins 0.000 claims abstract description 194
- 230000027455 binding Effects 0.000 claims abstract description 92
- 150000001413 amino acids Chemical class 0.000 claims abstract description 81
- 241000282414 Homo sapiens Species 0.000 claims abstract description 79
- 108010045030 monoclonal antibodies Proteins 0.000 claims abstract description 53
- 102000005614 monoclonal antibodies Human genes 0.000 claims abstract description 53
- 102000004218 Insulin-like growth factor I Human genes 0.000 claims abstract description 30
- 108090000723 Insulin-like growth factor I Proteins 0.000 claims abstract description 30
- 230000003042 antagnostic Effects 0.000 claims abstract description 29
- 239000005557 antagonist Substances 0.000 claims abstract description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 201000011510 cancer Diseases 0.000 claims description 18
- 210000004408 Hybridomas Anatomy 0.000 claims description 16
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 15
- 201000001320 atherosclerosis Diseases 0.000 claims description 15
- 102100004476 SIRPA Human genes 0.000 claims description 14
- 101710024246 SIRPA Proteins 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 206010038932 Retinopathy Diseases 0.000 claims description 6
- 206010038923 Retinopathy Diseases 0.000 claims description 6
- 230000001809 detectable Effects 0.000 claims description 6
- 208000001083 Kidney Disease Diseases 0.000 claims description 5
- 206010029149 Nephropathy Diseases 0.000 claims description 5
- 206010029151 Nephropathy Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000001225 therapeutic Effects 0.000 claims description 5
- 201000008739 coronary artery disease Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 102100013078 CD47 Human genes 0.000 abstract description 212
- 101700033237 CD47 Proteins 0.000 abstract description 212
- 239000000758 substrate Substances 0.000 abstract description 4
- 108020000494 Protein Tyrosine Phosphatases Proteins 0.000 abstract description 3
- 102000002727 Protein Tyrosine Phosphatases Human genes 0.000 abstract description 3
- 210000004027 cells Anatomy 0.000 description 166
- 235000001014 amino acid Nutrition 0.000 description 60
- 241000700159 Rattus Species 0.000 description 48
- 238000006366 phosphorylation reaction Methods 0.000 description 47
- 230000000865 phosphorylative Effects 0.000 description 47
- 235000018102 proteins Nutrition 0.000 description 33
- 238000000034 method Methods 0.000 description 32
- 230000000694 effects Effects 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 26
- 230000003993 interaction Effects 0.000 description 25
- 239000003795 chemical substances by application Substances 0.000 description 24
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 23
- 102000038027 MAP kinase family Human genes 0.000 description 21
- 108091007472 MAP kinase family Proteins 0.000 description 21
- 210000002889 Endothelial Cells Anatomy 0.000 description 20
- 238000002318 immunoblotting Methods 0.000 description 20
- 102000005962 receptors Human genes 0.000 description 20
- 108020003175 receptors Proteins 0.000 description 20
- 102000018358 Immunoglobulins Human genes 0.000 description 17
- 108060003951 Immunoglobulins Proteins 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 239000000427 antigen Substances 0.000 description 16
- 150000002500 ions Chemical class 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 230000011664 signaling Effects 0.000 description 16
- 108091007172 antigens Proteins 0.000 description 15
- 102000038129 antigens Human genes 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 206010012601 Diabetes mellitus Diseases 0.000 description 14
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 206010012689 Diabetic retinopathy Diseases 0.000 description 13
- 239000003102 growth factor Substances 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 230000004663 cell proliferation Effects 0.000 description 12
- 102000006495 integrins Human genes 0.000 description 12
- 108010044426 integrins Proteins 0.000 description 12
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 11
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 11
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 11
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 11
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 229960000060 monoclonal antibodies Drugs 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 239000006166 lysate Substances 0.000 description 10
- 239000002609 media Substances 0.000 description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 9
- 229940035295 Ting Drugs 0.000 description 9
- 230000035492 administration Effects 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 238000005755 formation reaction Methods 0.000 description 9
- 230000035699 permeability Effects 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 8
- 210000004369 Blood Anatomy 0.000 description 8
- 230000035693 Fab Effects 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004881 tumor cells Anatomy 0.000 description 8
- 210000001736 Capillaries Anatomy 0.000 description 7
- 229920002676 Complementary DNA Polymers 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 108091006028 chimera Proteins 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000001965 increased Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 235000002374 tyrosine Nutrition 0.000 description 7
- -1 without limitation Substances 0.000 description 7
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 6
- 229920000272 Oligonucleotide Polymers 0.000 description 6
- 108091000081 Phosphotransferases Proteins 0.000 description 6
- 102000001253 Protein Kinases Human genes 0.000 description 6
- 210000001525 Retina Anatomy 0.000 description 6
- 210000002966 Serum Anatomy 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000003902 lesions Effects 0.000 description 6
- 230000002934 lysing Effects 0.000 description 6
- 101710022144 mouse Iap Proteins 0.000 description 6
- 230000001105 regulatory Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102000003940 Occludin Human genes 0.000 description 5
- 108090000304 Occludin Proteins 0.000 description 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 230000000903 blocking Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 238000000975 co-precipitation Methods 0.000 description 5
- 230000000295 complement Effects 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- 238000000326 densiometry Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 108091008117 polyclonal antibodies Proteins 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 4
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 4
- 208000007342 Diabetic Nephropathy Diseases 0.000 description 4
- 206010061835 Diabetic nephropathy Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 4
- 102000006649 Mitogen-Activated Protein Kinase 3 Human genes 0.000 description 4
- 108010087271 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 4
- 229960001052 Streptozocin Drugs 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 230000001086 cytosolic Effects 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 4
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000001963 growth media Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- CAHCBJPUTCKATP-FAWZKKEFSA-N (-)-Etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 3
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 3
- 210000001772 Blood Platelets Anatomy 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- KBNIFDASRCWYGC-GXNXWABVSA-J Evans blue Chemical compound [Na+].[Na+].[Na+].[Na+].C\1=CC2=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C(N)=C2C(=O)C/1=N/NC(C(C)=C1)=CC=C1C1=CC=C(N\N=C/2C(C3=C(N)C(=CC(=C3C=C\2)S([O-])(=O)=O)S([O-])(=O)=O)=O)C(C)=C1 KBNIFDASRCWYGC-GXNXWABVSA-J 0.000 description 3
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 3
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 102000006652 Mitogen-Activated Protein Kinase 1 Human genes 0.000 description 3
- 108010087267 Mitogen-Activated Protein Kinase 1 Proteins 0.000 description 3
- 229960001592 Paclitaxel Drugs 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 210000000952 Spleen Anatomy 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000003143 atherosclerotic Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 238000006209 dephosphorylation reaction Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 230000000051 modifying Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229930003347 taxol Natural products 0.000 description 3
- 108060005293 AGA Proteins 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 102100004323 ASPG Human genes 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 210000000709 Aorta Anatomy 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 102000000905 Cadherins Human genes 0.000 description 2
- 108050007957 Cadherins Proteins 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 229960000684 Cytarabine Drugs 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 229960003699 Evans blue Drugs 0.000 description 2
- 241000272184 Falconiformes Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 125000002068 L-phenylalanino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 210000002540 Macrophages Anatomy 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 101700079659 PTP-2 Proteins 0.000 description 2
- 229940049954 Penicillin Drugs 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010043958 Peptoids Proteins 0.000 description 2
- 229940072417 Peroxidase Drugs 0.000 description 2
- 108090000437 Peroxidases Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 2
- 229960005322 Streptomycin Drugs 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 210000003462 Veins Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000118 anti-eoplastic Effects 0.000 description 2
- 230000001028 anti-proliferant Effects 0.000 description 2
- 230000000692 anti-sense Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229960000626 benzylpenicillin Drugs 0.000 description 2
- 230000000973 chemotherapeutic Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000001472 cytotoxic Effects 0.000 description 2
- 230000002939 deleterious Effects 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000001605 fetal Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000004030 hiv protease inhibitor Substances 0.000 description 2
- 230000002209 hydrophobic Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 230000002147 killing Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 230000003278 mimic Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 101700083626 pyp2 Proteins 0.000 description 2
- 230000002285 radioactive Effects 0.000 description 2
- 230000026267 regulation of growth Effects 0.000 description 2
- 230000002207 retinal Effects 0.000 description 2
- 235000020945 retinal Nutrition 0.000 description 2
- 239000011604 retinal Substances 0.000 description 2
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 238000003530 single readout Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 102000035402 transmembrane proteins Human genes 0.000 description 2
- 108091005683 transmembrane proteins Proteins 0.000 description 2
- 150000003668 tyrosines Chemical class 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N (2S)-2-acetamido-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- SXFWKZNLYYRHMK-UHFFFAOYSA-N 1H-indolo[7,6-f]quinoline Chemical compound C1=CC=C2C3=C(NC=C4)C4=CC=C3C=CC2=N1 SXFWKZNLYYRHMK-UHFFFAOYSA-N 0.000 description 1
- HBOCNGZYIAZFSU-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-2-(phosphonoamino)propanoic acid Chemical compound OP(=O)(O)NC(C(=O)O)CC1=CC=C(O)C=C1 HBOCNGZYIAZFSU-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 241001479434 Agfa Species 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100004728 CDH1 Human genes 0.000 description 1
- 101700016900 CDH1 Proteins 0.000 description 1
- 102100005704 CDH13 Human genes 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N CN(C)\N=N\c1[nH]cnc1C(N)=O Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 229960004117 Capecitabine Drugs 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 210000004671 Cell-Free System Anatomy 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 241000581364 Clinitrachus argentatus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 210000004292 Cytoskeleton Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 208000001636 Diabetic Neuropathy Diseases 0.000 description 1
- 206010012680 Diabetic neuropathy Diseases 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 229940121647 EGFR inhibitors Drugs 0.000 description 1
- 229940022766 EGTA Drugs 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 102000027757 FGF receptors Human genes 0.000 description 1
- 108091008101 FGF receptors Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 108010066705 H-cadherin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 210000002837 Heart Atria Anatomy 0.000 description 1
- 210000001308 Heart Ventricles Anatomy 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 229940022353 Herceptin Drugs 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 102000038595 IGF Type 1 Receptor Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N Iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 108050003490 Insulin-like growth factor Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 241001527806 Iti Species 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 229920000126 Latex Polymers 0.000 description 1
- 206010024190 Leiomyosarcomas Diseases 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 229940008250 Leuprolide Drugs 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- LAZPBGZRMVRFKY-HNCPQSOCSA-N Levamisole hydrochloride Chemical compound Cl.C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 LAZPBGZRMVRFKY-HNCPQSOCSA-N 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102100014894 MMP2 Human genes 0.000 description 1
- 101700060512 MMP2 Proteins 0.000 description 1
- 102100006844 MMP9 Human genes 0.000 description 1
- 101700067851 MMP9 Proteins 0.000 description 1
- 101700032853 MUC4 Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 229940105631 Nembutal Drugs 0.000 description 1
- 241000750002 Nestor Species 0.000 description 1
- 102000005608 Neuronal Cell Adhesion Molecules Human genes 0.000 description 1
- 108010059604 Neuronal Cell Adhesion Molecules Proteins 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N O(4)-phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 102100013355 PNPLA2 Human genes 0.000 description 1
- 101710027913 PNPLA2 Proteins 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N Pepstatin Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-Kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-Kinases Proteins 0.000 description 1
- 241001377010 Pila Species 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N Pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102200007540 RC3H2 C33S Human genes 0.000 description 1
- 210000001957 Retinal Vein Anatomy 0.000 description 1
- 102100000677 SLTM Human genes 0.000 description 1
- 101700001014 SLTM Proteins 0.000 description 1
- 101700058207 SPP1 Proteins 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- 210000000115 Thoracic Cavity Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- 229950001353 Tretamine Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 210000003606 Umbilical Veins Anatomy 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000024126 agglutination involved in conjugation with cellular fusion Effects 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 201000002936 artery disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
- 108040002558 cell adhesion mediator activity proteins Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001411 chlormethine Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 201000011024 colonic benign neoplasm Diseases 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000002962 histologic Effects 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000003345 hyperglycaemic Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002621 immunoprecipitating Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000000366 juvenile Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 244000123579 maile Species 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 229930014626 natural products Natural products 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 108010038010 porcine apoptosis protein inhibitor Proteins 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000013533 rum Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002784 sclerotic Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 101710040918 shg Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 101710044770 sll1951 Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 108091005974 tyrosine-phosphorylated proteins Proteins 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
Abstract
Disclosed is a monoclonal antibody that specifically binds an epitope within amino acids 71-80 of the human IAP (integrin-associated protein) and is an antagonist of IAP to SHPS-1 (Src homology 2 domain-containing protein tyrosine phosphatase substrate 1) binding. Also disclosed is a method of inhibiting IGF-1 actions in a subject by the use of the antibody. iting IGF-1 actions in a subject by the use of the antibody.
Description
/052384
METHOD FOR INHIBITING CELLULAR ACTIVATION
BY INSULIN-LIKE GROWTH FACTOR-1
Priorifl Statement
This application claims priority to US. Application Serial No. 13/219,276,
filed August 26, 2011, the entire contents of which are incorporated herein by
reference.
Statement of ment Support
This invention was made with government t under grant number
AG02331 from the National Institutes of Health. The US. Government has certain
rights to this invention.
Field of the Invention
The present invention concerns methods for inhibiting IGF-l activity in
ts in need f, such as subjects afflicted with cancer, atherosclerosis,
nephropathy and/or retinopathy.
Background of the Invention
Insulin—like growth —I is required for generalized somatic growth, that is
the normal growth and development that occurs throughout childhood requires IGF—l.
If the IGF-l gene is deleted from mice, the mice are born at half of a normal size and
grow poorly after birth reaching approximately 30% of normal adult size. Therefore
this growth factor is an important mitogen for all known cell types.
Interest has emerged in ting IGF-l activation of mitogenesis in cells
because it has been shown that high trations of IGF-1 are linked to the
development of cancer whereas low concentrations of IGF—1 appear to be cancer
protective. For example, US. Patent No. 6,340,674 to Baserga et a1. describes an
antisense method of inhibiting proliferation of cancer cells by contacting the cancer
cells with an oligonucleotide substantially complementary to a region of IGF-1
receptor RNA and which specifically hybridizes to IGF-l receptor RNA.
In addition, IGF—l is synthesized in the local microenvironment in several
diseases that involve abnormal cellular repair. An important e of this type is
sclerosis, which is the leading cause of death in the United States. Cells in the
atherosclerotic lesion synthesize excess IGF-1 and therefore excess lGF-l signaling
leads to enlargement of lesions. Several studies have shown that if the effect of this
IGF—l is inhibited, lesion progression is retarded. Therefore there is cant
interest in inhibiting lGF-l action in vessel wall cell types such as smooth muscle
cells.
Traditional approaches to inhibiting IGF-l such as blocking ligand binding to
the IGF-l receptor have failed for two reasons: first, the g site is quite large
and therefore it is ult to design compounds that will effectively inhibit binding;
, there is a significant structural overlap between the IGF-l receptor and the
n receptor, and approaches that have attempted to alter IGF-l receptor activity
by blocking the ty of the or have invariably led to toxicity due to
coinhibition of the insulin or. Antisense techniques present the problem of
delivering the active agent to the interior of target cells. Thus there is a need for new
ways to inhibit IGF-l activity or production in cells of subjects in need of such
treatment.
Summary of the Invention
The present invention es a method of inhibiting cellular activation by
Insulin—like Growth Factor—1 (IGF—l) in a subject in need thereof [for example, a
subject that has or is at increased risk of having a , a tumor, atherosclerosis,
nephropathy (e.g., diabetic nephropathy) and/or retinopathy (e. g., diabetic
retinopathy)]. The method comprises administering an antagonist that inhibits the
binding of IAP to SHPS—l to the subject in an amount effective to inhibit cellular
activation by IGF-l (for example, an amount effective to treat the condition or
disorder or a ent effective amount).
One aspect of the present invention is a method of treating a tumor in a subject
(e.g., a subject in need thereof), comprising administering to the subject an IAP to
SHPS-l binding antagonist (e.g., an antibody of this invention) in an amount effective
to treat the tumor (e.g., an amount ive to inhibit the effect of lGF-l on the
tumor). Also included herein is a method of treating cancer in a subject (e.g., a
t in need thereof), comprising administering to the subject an effective amount
of an IAP to SHPS—l binding antagonist (e.g., an antibody of this invention).
Nonlimiting examples of cancers that may be treated according to the methods of this
invention include breast cancer, colon cancer, lung cancer, prostate cancer, acute
enous leukemia, le myeloma, Hodgkin's lymphoma, non-Hodgkin's
lymphoma, bladder cancer, leiomyosarcoma, ovarian cancer, glioblastoma and
hepatocellular carcinoma. Tumors to be treated include those that are associated with
any of the cancers listed above as well as any tumors that express IGF-l receptors.
Another aspect of the present invention is an improvement in a method of
treating a tumor in a subject in need thereof by administering a treatment effective
amount of an oplastic compound (i.e., a chemotherapeutic agent) and/or
radiation therapy to the subject, the improvement comprising administering to the
t an to IAP to SHPS—l binding antagonist in an amount effective to inhibit IGF-
1 mediated rescue of tumor cells (i.e., inhibit the anti—apoptotic effect of IGF-1 on
tumor cells).
A further aspect of the present ion is a method of treating atherosclerosis
in a subject in need thereof, sing administering to the subject an IAP to SHPS-
1 binding nist in an amount effective to treat the atherosclerosis. Any type of
sclerotic lesion may be treated, such as coronary, carotid and/or l
atherosclerosis. In general, atherosclerotic lesions to be treated are those in which the
lesion cells express IGF-l ors.
A further aspect of the present invention is a method of treating diabetic
nephropathy (e. g., diabetic nephropathy) in a subject in need thereof, comprising
administering to the subject an IAP to SHPS-l binding antagonist in an amount
effective to treat the nephropathy.
A further aspect of the present invention is a method of treating retinopathy
(e.g., diabetic pathy) in a subject in need thereof, comprising administering to
the subject an IAP to SHPS-l binding antagonist in an amount effective to treat the
retinopathy.
A r aspect of the present invention is a method of treating coronary
artery disease in a subject in need thereof, comprising administering to the subject an
IAP to SHPS—l binding antagonist in an amount effective to treat the coronary artery
disease.
Antagonists that may be used in carrying out the s bed herein,
sometimes referred to herein as active , may be of any suitable type, including
proteins or peptides, such as antibodies or antigen binding fragments thereof.
Particular examples of antagonists that can be used to carry out the present invention
include but are not limited to antibodies that antagonize IAP to SHPS-l binding,
SHPS—l fragments comprising, consisting of‘or consisting ially .of the IAP
binding domain, IAP fragments comprising, ting of or consisting essentially of
the SHPS—l binding domain, analogs thereof, and/or non-peptide mimetics or analogs
f. In one embodiment of this invention, the antibody can be the monoclonal
antibody B6H12.
A further aspect of the present invention is a pharmaceutical ation
comprising an active agent (e.g., an antibody or antigen binding fragment thereof as
described herein in a pharmaceutically acceptable carrier.
A further aspect of the present invention is the use of an active agent as
described herein for the manufacture of a medicament for ng out a method of
treatment as described herein.
A further aspect of the present ion is an in vitro method of screening
compounds for activity in (i) inhibiting cellular activation by Insulin-like Growth
Factor—1 (for example, ting cell growth by IGF-l, (ii) treating cancers or tumors
(as described above), and/or (iii) treating atherosclerosis (as bed above), the
method sing the steps of: (a) adding or ting a test compound to an in
vitro system comprising the SHPS-l protein and the IAP protein; then (b) determining
whether the test compound is an antagonist of IAP to SHPS-l binding; and then (0)
identifying the test compound as active or potentially active in (z) inhibiting cellular
activation by Insulin—like Growth Factor —l, (ii) treating s or tumors, and/or (iii)
treating atherosclerosis when the test compound is an antagonist of IAP to SHPS—l
binding.
The present invention also provides a monoclonal antibody that specifically
binds an epitope within amino acids 71-80 (i.e., the peptide ALNKSTVPTD, SEQ ID
NO:6) of the human IAP protein (amino acid numbering is based on the amino acid
sequence of SEQ ID N027) and is an antagonist of IAP to SHPS-l binding. A r
characteristic of the antibody is that it does not disrupt IAP binding to a [33 protein.
The numbering of the amino acids for human IAP is based on the reference amino
acid sequence of GenBank® Database ion No. NP_942088 (incorporated by
reference herein) and is as follows, with the first amino acid numbered 1 and the last
amino acid numbered 305. Amino acid residues 71-80 are bolded in the sequence
below.
MWPLVAALLL GSACCGSAQL LFNKTKSVEF TFCNDTVVIP EAQN
TTEVYVKWKF KGRDIYTFDG ALNKSTVPTD FSSAKIEVSQ LLKGDASLKM
DKSDAVSHTG NYTCEVTELT REGETIIELK FSPN ENILIVIFPI
FAILLFWGQF GIKTLKYRSG GMDEKTIALL TVIVIV GAILFVPG
ATGL GLIVTSTGIL ILLHYYVFST AIGLTSFVIA ILVIQVIAYI
LAVVGLSLCI AACIPMHGPL ILAL AQLLGLVYMK FVASNQKTIQ
PPRNN (SEQ IN NO:7).
The monoclonal dy described above can be the monoclonal antibody
ed by oma NPG-1, or a monoclonal antibody that competes for binding
to the same epitope as the epitope bound by a monoclonal antibody produced by the
hybridoma NPG-1. Hybridoma NPG-1 was deposited with the American Type
Culture Collection (ATCC; Manassas, VA) on August 17, 2012 and assigned
Accession No. PTA-13161.
Additionally provided herein is a method of ting IGF-1 actions in a
subject in need thereof, comprising administering to the subject an antibody or
antigen binding fragment thereof of this invention.
Further provided is a method of ng diabetic retinopathy, diabetic
atherosclerosis, diabetic nephropathy and/or ry artery disease in a subject (e.g.,
a subject in need thereof), comprising administering to the subject an effective
amount of the antibody or antigen binding nt thereof of this invention. In such
methods the antibody can, in some embodiments be administered by subcutaneous
injection and/or intravenous infusion.
Brief Description of the Drawings
Figures 1A-C. Co-precipitation of IAP with SHPS-1 and disruption with anti-
IAP antibody, B6H12. A. Cell lysates were immunoprecipitated with an anti IAP
antibody and co-precipitation of SHPS-1 determined by immunoblotting with anti
SHPS-1 antiserum or immunoprecipitated with SHPS-1 and co-precipitation of IAP
determined by immunblotting with an anti IAP antibody. As a l, cell lysates
were also immunoprecipitated with an irrelevant polyclonal antibody (IgG) and
immunoblotted with an anti IAP antibody. B. Quiescent pSMCs were incubated for
two hours ± the addition of the anti IAP monoclonal antibody, B6H12, or an
vant control monoclonal antibody (both at 4 µg/ml). Co-precipitation of IAP
with SHPS-1 was then determined by immunoprecipitating with an SHPS-1 antibody
and immunoblotting with an anti IAP antibody. The amount of SHPS-1 protein in
each lane is shown in the lower panel. C. Expression of FLAG labeled IAP and
association with SHPS-l. Top panel: Expression of FLAG labeled IAP was
determined by immunblotting whole cell lysates from cells transfected with each of
the IAP cDNA constructs using an anti FLAG antibody. The results as scanning units
are: Lane 8, Lane 2:39.274, Lane 3246779. Lower panels: Cell lysates were
immunoprecipitated with an anti—SHPS—l antibody then co—precipitation of FLAG
labeled IAP was determined by immunoblotting with an anti FLAG dy. The
amount of SHPS-l that was immunoprecipitated in each lane is shown in the lower
panel.
Figures 2A—C. A. SHPS—l phosphorylation and SHP-2 recruitment to SHPS—
l in response to lGF—l following disruption of the association between IAP and
SHPS—l by the anti IAP antibody, B6H12. Quiescent cells were incubated for two
hours i B6Hl2 antibody or vant control monoclonal antibody (both at 4 rig/ml)
then d to IGF-l (100 ng/ml) as ted. Cell lysates were immunoprecipitated
with an anti—SHPS-l antibody then SHPS-l orylation was determined by
immunoblotting with an antiphosphotyrosine antibody (p—Tyr). The association of
SHP-2 with SHPS-l was ized by immunoblotting using an anti SHP-2 dy.
The amount of SHPS-l protein in each lane is shown in the lower panel. The increase
in SHPS—l phosphorylation and SHP—2 recruitment following IGF-l stimulation as
determined by scanning densitometry analysis of western immunoblots from three
separate experiments is shown. ** p <0.05 when cells preincubated with B6H12 are
compared with cells preincubated in SFM alone. B SHPS—l phosphorylation and
SHP-2 recruitment in response to IGF—l following disruption of the association
between IAP and SHPS-l in cells expressing mutated forms of IAP. Cells were
exposed to IGF-l (100 ng/ml). for various periods. Cell lysates were
immunoprecipitated with an anti—SHPS-l antibody and SHPS—l phosphorylation was
determined by immunoblotting with an antiphosphotyrosine antibody (pTyr). The
association of SHP—2 was Visualized by immunoblotting using an anti SHP-2
antibody. The amount of SHPS—l protein in each lane is shown in the lower panel.
The increase in SHPS-l phosphorylation and SHP-2 tment following IGF-l
ation as ined by scanning densitometry analysis of western immunoblots
from three separate experiments is shown. ** p <0.05 when cells expressing mutant
forms of IAP are compared with cells expressing IAP fl. C. SHPS—l phosphorylation
in response to PDGF. Cells were exposed to PDGF (10 ng/ml) for 5 minutes.
Following cell lysis and immunoprecipitation with an anti SHPS-l antibody SHPS-l
phosphorylation was determined by immunoblotting with an anti phosphotyrosine
antibody (pTyr).
Figures 3A-B. IGF-lR phosphorylation time course and SHP-2 recruitment
following disruption of the interaction between IAP and SHPS-l. A. Quiescent cells
were incubated i anti—IAP antibody, B6H12 (4 ug/ml) then exposed to IGF—l (100
ng/ml) for various lengths of time. Following lysis and immunoprecipitation with an
anti IGF—lR antibody phosphorylation of [the or was determined by
immunoblotting with an anti phosphotyrosine antibody (pTyr). The association of
SHP-2 was determined by immunoblotting with an anti SHP—2 antibody. The amount
of IGF-lR protein in each lane is shown in the lower panel. The level of tyrosine
phosphorylation of IGF-lR as a percentage of maximum phosphorylation detected as
determined by scanning densitometry analysis of n immunoblots from three
separate experiments is shown. The increase in SHP-2 recruitment ing IGF-l
stimulation as determined by scanning densitometry is of western immunoblots
from three separate experiments is also shown. ** p <0.05 when cells preincubated
with B6H12 are ed with cells preincubated in SFM alone. B. Cells were
incubated with IGF-l (100 ng/ml) for various times. Following lysis and
immunoprecipitation with an anti IGF—lR dy phosphorylation of the receptor
was determined by immunoblotting with an anti phosphotyrosine antibody (pTyr).
The ation of SHP-2 was determined by immunoblotting with an anti SHP—Z
antibody. The amount of lGF—lR protein in each lane is shown in the lower panel.
The changes in IGF—lR phosphorylation and SHP-Z recruitment following IGF—l
stimulation as determined by ng densitometry analysis of western immunoblots
from three separate experiments are shown. **p <0.05 when cells expressing lAPc—s
are compared with cells expressing IAP fl.
s 4A-B. A. Phosphorylation of MAPK in response to IGF-l. Cells
were plated and grown prior to a 2—hour incubation :t the AP dy, B6H12
or irrelevant control monoclonal antibody (both at 4 ug/ml) and then treated with
IGF-l (100 ng/ml) for 10 minutes. The level of p42/44 MAPK phosphorylation was
determined by immunoblotting with a phosphospecific MAPK antibody. The total
amount of MAPK in each sample was determined by immunoblotting with a MAPK
antibody. B. Cells were plated and grown prior to a 2 hour incubation i B6H12 or an
irrelevant control monoclonal antibody (both at a concentration of 4 ug/ml) and then
treated with IGF -I (100 ng/ml) for 48 hours. Cell number in each well was then
determined. Each data point represents the mean of three independent experiments.
**p = < 0.05 when cell number in the cultures incubated in the presence of B6H12 are
compared with cell number in the cultures incubatedvin the absence of antibody.
Figure 5. IGF—l stimulated cell migration in cells expressing full—length IAP
and IAP C-S. Confluent cells were wounded and then incubated i IGF-l (100 ng/ml)
for 48 hours. The number of cells migrating across the wound edge in at least 5 pre—
selected regions was counted. Each data point represents the mean :I: S.E.M. of three
independent experiments. **
p <0.05 when ion in the presence of IGF-1 is
compared with tion in SFM alone.
Figures 6A-D. Human endothelial cells were exposed to the anti-IAP
dy and lysates were immunoprecipitated with anti—SHPS—l and then
immunoblotted for IAP or Shc. A. The monoclonal dy NPG—l can disrupt IAP
binding to SHPS—l. Cells were ubated with NPG-l and then SHPS—l was
immunoprecipitated and the immunoprecipitate was immunoblotted for IAP. B. She,
which has to bind to SHPS—l to be activated in endothelial cells does not bind
normally if the cells are cubated with NPG—l antibody. C. The NPG—l antibody
specifically disrupts IAP binding to SHPS—l without disrupting IAP binding to B3. D.
SHPS—l association with IAP was determined in the aorta homogenates from control
(Con), diabetic (D) and diabetic rats treated with the anti—IAP antibody (R569) (D +
AB).
Figures 7A-C. In vitro assay of capillary formation. A. Cell permeability
measured in vitro based on dextran blue permeation. IGF—l stimulates permeation
and this is inhibited in the presence of the NPG—l dy (IAPab). B. The tight
junction protein occludin, which allows endothelial cells to form a permeability
barrier is disrupted in the presence of IGF-1, resulting in occludin g the
junctional complex that is normally formed and diffusing out into the cell. In the
presence of NPG—l dy, this effect of IGF—1 is completely inhibited. C.
Photomicrographs of elial cell tube formation. In IGF—l treated cells, tube
formation can be seen (upper right panel), where the capillary cells are g each
other with capillary tubes. In the presence of NPG-l antibody, this is completely
disrupted, as shown in the lower two panels and on the bar graph, where the number
of tubes per cm2 is shown.
Figures 8A-B .Rat endothelial cells were cultured in 25mM glucose.
Following overnight in SFM cells were incubated with (AB) or without (Con) the
anti—IAP antibody (R569), prepared using the rat IAP sequence NKNSTTREQN
(SEQ ID NO:8), which are amino acids 71—80 of the rat IAP sequence; numbering is
based on the amino acid sequence ofNCBI Reference Sequence Accession No.
NP_062068 [MWPLAAALLL GSCCCGSAQL LLSKVKSVEF TSCNDTVVIP
CKVLNVEAQS TDEMFVKWKL NKSYIFIYDG REQN FTSAKISVSD
SLTM DTHEAVVGNY TCEVTELSRE GKTVIELKNR PVSWFSTNEK
PILA ILLFWGKFGI LTLKYKSSHT NKRIILLLVA GLALTLIVVV
GAILFIPGEK PVKNASGLGL IVISTGILIL LQYNVFMTAF GMTSFTIAIL
ITQVLGYVLA VVGMCLCIMA CEPVHGPLLI ALAE LLGLVYMKFV
ASNQRTIQPP RNN (SEQ ID . For dy production, this ce was
linked to KLH as an immunogen according to known methods. A. l antibody
had no effect on IAP/SHPS-l association, whereas the anti-rat IAP antibody
completely disrupted this association. B. Following IGF-l stimulation, there is
tyrosine orylation of SHPS-l, stimulation ofAKT and MAPK activation.
These are inhibited in the presence of the anti-rat IAP antibody.
Figure 9. Vascular permeability. Non diabetic rats are shown as Control
(N=5). The diabetic rats were d with control IgG (N=12) or IgG purified from
antiserum that contained the anti—rat IAP antibody described herein (N=14) by protein
A ose chromatography. After three weeks the animals were anesthetized and
then ar permeability was measured. The anti-rat IAP IgG significantly
inhibited retinal vein vascular permeability, which is one of the first changes that
occurs in diabetic retinopathy.
Detailed ption of the Invention
The present invention is explained in greater detail below. This description is
not intended to be a detailed catalog of all the different ways in which the invention
may be implemented, or all the features that may be added to the instant invention.
For example, features illustrated with respect to one embodiment may be incorporated
into other embodiments, and features rated with respect to a particular
embodiment may be deleted from that embodiment. In addition, numerous variations
2012/052384
and additions to the s embodiments ted herein will be apparent to those
skilled in the art in light of the instant disclosure which do not depart from the instant
invention. Hence, the ing specification is intended to illustrate some particular
embodiments of the invention, and not to exhaustively specify all permutations,
combinations and variations thereof.
Subjects that may be treated by the present invention include both human .
subjects for medical purposes and animal subjects for veterinary and drug screening
and pment purposes. Other suitable animal subjects are, in general,
mammalian subjects such as humans, primates, bovines, ovines, es, porcines,
equines, felines, canines, lagomorphs, rodents (e. g., rats and mice), etc. Human
subjects are the most preferred. Human subjects include fetal, neonatal, infant,
juvenile and adult subjects.
"IGF-l " as used herein means insulin—like growth factor-1.
"IGF-lR" as used herein means an lGF—l receptor.
"IAP" as used herein means integrin associated protein. IAP. may be of any
type but is preferably mammalian IAP (e. g., human, mouse, rat, rabbit, monkey, pig,
etc), and is most preferably human IAP. MP (sometimes also called CD47)-is known
and described in, for example, E. Brown et al. J Cell Biol 111:2785-94 (1990); C. ,
Rosales et al. J Immunol 149:2759—64 (1992); D. Cooper et al. Proc Natl Acad Sci
USA 92:3978—82 (1995); P. Jiang et a1. JBiol Chem 274:559-62 (1999); P. Oldenborg
et al. Science 288:2051-4 (2000); M. Seiffert et al. Blood 94:3633—43 (1999); E.
Vemon—Wilson et al. Eur J Immunol 30:2130—2137 (2000); H. Yoshida et al. J
Immunol 168:3213-20 (2002); and I. Babic et al. JImmunol 164:3652—8 (2000).
l" as used herein means src homology 2 domain containing n
tyrosine phosphatase ate 1. SHPS—l may be of any type but is preferably
mammalian SHPS—l (e.g., human, mouse, rat, , monkey, pig, etc.), and is most
ably human SHPS-l. SHPS—l (sometimes also called P84) is known and
described in, for example, T. Noguchi et al., J Biol Chem 271, 27652-8 (1996); Y.
Fujioka et al., Mol Cell Biol 16, 6887—99 (1996); A. Kharitonenkov et al., Nature 386,
181—6 (1997); M. Stofega eta1.,JBiol Chem 273, 7112—7 ; and T. Takada et al.,
JBiol Chem 273, 9234-42 (1998).
"SHP-2" as used herein means src homology 2 ning protein tyrosine
phosphatase—2.
W0 2013f032948
“Treat,” “treating” or “treatment” as used herein refers to any type of action
that imparts a benefit to a subject that has a disease or disorder or is at risk of
developing the disease or er, including improvement in the condition of the
subject (e. g., in one or more symptoms), delay in the progression of the disease, delay
in the onset of symptoms and/or slowing of the progression of symptoms, etc. As
such, in some embodiments, the term “treatment” can include prophylactic treatment
of the subject to t the onset of symptoms. As used herein, the terms “treat” or
“treatment” are not necessarily meant to imply cure or complete abolition of
symptoms.
“Treatment effective amount,” "amount effective to treat,9’ “effective amount”
or the like as used herein means an amount of an antagonist (e.g., an antibody or
antigen binding nt f) sufficient to produce a desirable and/or beneficial
effect upon a subject that has a cancer, a tumor, atherosclerosis, retinopathy,
nephropathy, or other undesirable medical condition in which IGF—l is inducing
abnormal cellular growth. This es improvement in the condition of the patient
(6.g in one or more symptoms), delay in the progression of the disease, etc.
“Pharmaceutically acceptable” as used herein means that the nd or
composition is suitable for administration to a subject to e a beneficial and/or
ent effective outcome as described herein, without unduly deleterious. side
effects in light of the severity of the disease or er and necessity of the treatment.
Applicants ically intend that all patents, patent ations,
international patent publications and non-patent references cited herein be
incorporated by reference herein in their ty.
A. Antibodies.
The term “antibody” as used herein refers to all types of immunoglobulins,
including IgG, IgM, IgA, lgD, and lgE. The term “immunoglobulin” includes the
subtypes of these immunoglobulins, such as IgGl, IgGZ, IgG3, IgG4, etc. Of these
immunoglobulins, IgM and IgG are preferred, and IgG is particularly preferred. The
antibodies may be of any species of origin, including (for example) mouse, rat, rabbit,
horse, or human, or may be chimeric antibodies. See, e.g., M. Walker et a1. Molec.
Immunol. 26, 403—11 (1989). An dy of this invention can be a polyclonal
antibody or a monoclonal antibody. Such antibodies are produced in accordance with
known techniques. The term “antibody” as used herein also includes dy
fragments that retain the capability of binding to a target n (e.g., an antigen
binding fragment thereof, for e, Fab, F(ab’)2, and Fv fragments, and the
corresponding fragments obtained from antibodies other than IgG. Such fragments
are also produced by known techniques.
Antibody fragments included within the scope of the present invention ,,
include, for example, Fab, Fab', F(ab‘)2, and Fv fragments; domain antibodies,
diabodies; vaccibodies, linear dies; single—chain antibody molecules; and
multispecific antibodies formed from antibody fragments. Such fragments can be
produced by known techniques. For example, F(ab')2 fragments can be produced by
pepsin digestion of the antibody molecule, and Fab fragments can be generated by
reducing the disulfide bridges of the 2 fragments. Alternatively, Fab expression
ies can be constructed to allow rapid and easy identification of monoclonal Fab -
fragments with the desired specificity (Huse et al. Science 25421275 (1989)).
Monoclonal dies may be recombinant monoclonal antibodies produced
according to the methods disclosed, for e, in Reading US. Pat. No. 4,474,893, '
or Cabilly et al., US. Pat. No. 4,816,567. The antibodies may also be chemically
constructed by specific antibodies made ing to the method disclosed in Segel et
al., US. Pat. No. 4,676,980.
Monoclonal Fab fragments may be produced in Escherichia coli by
recombinant techniques known to those skilled in the art. See, e.g., W. Huse, Science
246:1275-81 (1989).
Antibodies for use in the present invention cally bind to their target with
a relatively high binding affinity, for example, with a dissociation constant of about
10'6 or 108, up to 10'12 or 10'”.
zed monoclonal antibodies that are antagonists of IAP to SHPS—l'
binding are a r aspect of the present invention. A humanized antibody of the
present invention may be produced from antibodies as described herein by any
suitable technique, using a conventional complementarity determining region (CDR)—
grafting method as disclosed, for example, in lication No. 0239400 and in'
US. Patent Nos. 6,407,213; 6,180,370; and 5,693,762, all of which are orated
herein by reference in their entirety. Alternatively, a humanized antibody may be
produced by directly modifying antibody variable regions t diminishing the
native affinity of the domain for antigen while reducing its genicity with
respect to a heterologous species (see, e.g., US. Patent No. 5,766,886, which is
incorporated herein by reference in its entirety).
Using a CDR-grafting method, the humanized antibody is generally produced
by combining a human framework region (FR) with one or more CDRs from a non—
human (usually a mouse or rat) immunoglobulin that are capable of binding to a
predetermined antigen.
Typically, the humanized antibody comprises substantially all of at least one,
and typically two, variable domains (Fab, Fab‘, F(ab‘)2, Fabc, FV) in which all or
substantially all of the CDRs correspond to those of a non—human immunoglobulin
and all or substantially all of the FRs are those of a human immunoglobulin consensus
sequence. The humanized antibody optimally also comprises at least a portion of an
.immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
rily, the dy contains both the light chain as well as at least the le
domain of a heavy chain. The antibody also may include the CH1, hinge, CH2, CH3,
and CH4 regions of the heavy chain.
The humanized dy may be selected from any class of immunoglobulins,
ing IgM, IgG, IgD, IgA and IgE, and any isotype, including IgGl, Ing, IgG3
and IgG4. Usually the constant domain is a complement fixing constant domain
where it is desired that the humanized antibody exhibit cytotoxic activity, and the
class is lly IgGl. Where such cytotoxic activity is not desirable, the constant
domain may be of the Ing class. The humanized dy may comprise sequences
from more than one class or isotype, and selecting particular constant domains to
optimize desired effector functions is within the ordinary skill in the art.
The FR and CDR of the humanized dy need not correspond precisely to
the parental sequences. At least about 75% of the humanized antibody residues can
correspond to those of the parental FR and CDR sequences, in some ments,
about 90%, and in some embodiments, greater than about 95%.
dies of the invention may be altered or mutated for compatibility with
species other than the species in which the dy was produced. For e,
antibodies may be humanized or camelized. Humanized forms of non—human (e.g.,
) antibodies are chimeric immunoglobulins, immunoglobulin chains or
fragments thereof (such as FV, Fab, Fab', F(ab')2 or other antigen-binding
subsequences of antibodies) which contain minimal sequence derived from non-
human immunoglobulin. Humanized antibodies include human immunoglobulins
ient antibody) in which residues from a complementarity determining region
(CDR) of the recipient are replaced by residues from a CDR of a non—human species
(donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity
and capacity. In some instances, Fv framework residues of the human
immunoglobulin are ed by corresponding non—human residues. Humanized
antibodies may also comprise residues which are found neither in the recipient
, antibody nor in the imported CDR or framework sequences. In general, the
zed antibody will comprise substantially all of at least one, and typically two,
variable domains, in which all or substantially all of the CDR regions correspond to
those of a non—human immunoglobulin and all or substantially all of amework
(FR) regions (i.e., the sequences n the CDR regions) are those of a human
immunoglobulin consensus ce. The humanized antibody optimally also will
se at least a portion of an globulin constant region (Fc), typically that
of a human immunoglobulin (Jones et al., Nature 321:522 (1986); ann et al.,
, 332:323 (1988); and Presta, Curr. 0p. . Biol. 2:593 (1992)).
Methods for humanizing non-human antibodies are well known in the art. .
Generally, a humanized antibody has one or more amino acid residues introduced into
it from a source which is non—human. These non-human amino acid residues are
often referred to as t" residues, which are typically taken from an "import"
variable domain. Humanization can essentially be performed following the method of
Winter and co—workers (Jones et al., Nature 321:522 (1986); Riechmann et al., Nature
332:323 (1988); Verhoeyen et al., Science 239:1534 (1988)), by substituting rodent
CDRs or CDR sequences for the corresponding sequences of a human antibody.
Accordingly, such "humanized" antibodies are chimeric antibodies (US. Patent No.
4,816,567), wherein ntially less than an intact human variable domain has been
substituted by the corresponding sequence from a non—human species. In practice,
humanized antibodies are typically human antibodies in which some CDR residues
(e.g., all of the CDRs Or a n thereof) and possibly some FR residues are
substituted by residues from analogous sites in rodent dies.
Human antibodies can also be produced using various techniques known in the
art, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol. 22 7:381
(1991); Marks et al., J. Mol. Biol. 2222581 . (1991)). The techniques of Cole et al. and
Boerner et al. are also available for the ation of human monoclonal antibodies
(Cole et at, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985)
and Boerner et al., J. Immunol. 14 7:86 (1991)). rly, human antibodies can be
made by introducing human imrnunoglobulin loci into transgenic animals, e.g. , mice
in which the endogenous immunoglobulin genes have been partially or completely
vated. Upon nge, human antibody tion is observed, which closely
resembles that seen in humans in all respects, including gene rearrangement,
assembly, and antibody repertoire. This approach is described, for example,.in US.
Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in
the following scientific ations: Marks et al., Bio/Technology 102779 (1992);
Lonberg et al., Nature 3681856 (1994); Morrison, Nature 2 (1994); Fishwild et
al., Nature Biotechnol. 142845 (1996); Neuberger, Nature Biotechnol. 142826 (1996);
Lonberg and Huszar, Intern. Rev. Immunol. 13:65 (1995).
Polyclonal antibodies used to carry out the present invention can be produced
by immunizing a suitable animal (e.g., rabbit, goat, etc.) with an antigen to which a
onal dy to the target binds, collecting immune serum from the animal,
and separating the polyclonal antibodies from the immune serum, in ance with
known procedures.
onal antibodies used to carry out the present invention can be produced
in a hybridoma cell line according to the technique of Kohler and Milstein, Nature
265:495 (1975). For example, a solution containing the appropriate antigen can be
injected into a mouse and, after a sufficient time, the mouse sacrificed and spleen cells
obtained. The spleen cells are then immortalized by fusing them with a cells
or with ma cells, typically in the ce ethylene glycol, to produce
hybridoma cells. The hybridoma cells are then grown in a suitable medium and the
supernatant screened for monoclonal antibodies having the desired specificity.
Monoclonal Fab fragments can be produced inE. coli by recombinant techniques
known to those skilled in the art. See, e. g., Huse, Science 246:1275 .
Antibodies specific to the target polypeptide can also be obtained by phage
display techniques known in the art.
Monoclonal antibodies can be chimeric or "humanized" antibodies produced
in accordance with known techniques. For example, chimeric monoclonal antibodies
may be complementarily determining region—grafted antibodies (or “CDR—grafted
antibodies”) produced in accordance with known techniques.
An example of an antibody of this invention is monoclonal antibody B6H12
(e. g., B6H12.2 assigned ATCC ion No. l).
The t invention also provides a monoclonal antibody that specifically
binds an epitope within amino acids 71-80 of the human IAP protein (numbering
based on the amino acid sequence of SEQ ID N017) and is an antagonist of IAP to
SHPS-l binding. For example the antibody can bind an epitope comprising amino
acids 71-73,. 71-74, 71—75, 71-76, 71-77, 71-78, 71—79, 71-80, 72-74, 72—75, 72—76,
72~77, 72—78, 72-79, 72—80, 73-75, 73—76, 73-77, 73—78, 73-79, 73-80, 74-76, 74-77,
74-78, 74—79, 74—80, 75-77, 75—78, 75-79, 75—80, 76-78, 76—79, 76—80, 77-79, 77- 80
or 78—80 of the amino acid sequence of SEQ ID NO:7.
The present invention additionally provides a monoclonal antibody produced
by the hybridoma NPG—l, and called monoclonal antibody NPG-l herein. This
hybridoma was produced according to standard protocols for monoclonal antibody
production as are well known in the art. The immunogen administered to the mice
was the peptide ALNKSTVPTDC (SEQ ID , which represents amino acid
residues 71—80 (numbering based on the amino acid sequence of SEQ-ID N027) of the
human IAP amino acid sequence as provided herein (i.e., ALNKSTVPTD, SEQ ID
NO:6), with a cysteine residue added at the carboxyl terminus that was used to link
the peptide to keyhole limpet hemocyanin (KLH). Therefore, the actual immunogen
was a conjugate of the active peptide and KLH, linked by a cysteine. Mice were
immunized and then the spleens were harvested for fusion with myeloma cells. The
myeloma cell supernatants were screened by ELISA using the immunogen linked to
BSA to coat the plates. The positive supernatants were then ned four separate
times before the final clone producing the high affinity antibody was selected. The
numbering of the amino acids for human IAP is based on the reference amino acid
sequence of GenBank® Database ion No. NP_942088 (incorporated by
nce herein) and is as follows, with the first amino acid ed 1 and the last
amino acid numbered 305. Amino acid residues 71—80 are bolded in the sequence
below.
MWPLVAALLL GSACCGSAQL SVEF TFCNDTWIP CFVTNMEAQN
TTEVYVKWKF KGRDIYTFDG ALNKSTVPTD FSSAKIEVSQ SLKM
DKSDAVSHTG TELT REGETIIELK YRVVSWFSPN ENILIVIFPI
FAILLFWGQF GIKTLKYRSG GMDEKTIALL VAGLVITVIVIV GAILFVPG
EYSLKNATGL GLIVTSTGIL ILLHYYVFST AIGLTSFVIA ILVIQVIAYI
LAVVGLSLCI AACIPMHGPL LISGLSILAL AQLLGLVYMK FVASNQKTIQ
PPRNN (SEQ IN NO:7).
In some embodiments, the antibody is (a) the monoclonal dy produced
by hybridoma NPG-1, or (b) a monoclonal antibody that competes for binding to the
same epitope as the epitope bound by a monoclonal antibody produced by the
hybridoma NPG-1 (i.e., a monoclonal antibody that specifically binds to the e
bound by a monoclonal antibody produced by the hybridoma NPG-1).
oma NPG-1 was deposited with the American Type Culture tion
(ATCC) in Manassas, Virginia on August 17, 2012 and ed Accession Number
PTA-13161. This hybridoma produces an antibody of the present invention, as
bed herein.
The monoclonal dy NPG-1 binds to the human IAP protein and ts
IAP binding to SHPS-1 without disrupting IAP binding to 3 protein. The 3 integrin
subunit is a component of the v 3 integrin. It is expressed abundantly on the surface
of vascular endothelial cells. Agents which disrupt the function of v 3 integrin have
been shown to lead to changes in endothelial cell function as well as inhibition of
endothelial cell growth. Furthermore since this integrin t is expressed on
platelets, agents that have been shown to inhibit its function in platelets have been
shown to stimulate platelet aggregation which can lead to thrombosis. This is an
important distinguishing feature of this monoclonal antibody. Many antibodies that
react with human IAP also bind to v 3 integrin. Disrupting IAP binding to 3 could
lead to side effects, making the therapeutic use of such antibodies undesirable. The
NPG-1 antibody has the unexpected benefit of g to human IAP and disrupting
its association with SHPS-1 without disrupting IAP binding to 3.
Further provided herein is a humanized onal antibody NPG-1. The
humanized form of the antibody can be prepared using in vitro mutagenesis. The
complementarity determining regions (CDRs) are left intact unless it is necessary to
alter single amino acids with these regions to avoid or minimize genicity.
Similarly, the ork regions is scanned for regions that might confer
immunogenicity and the riate mouse amino acid residues are changed to
human amino acid residues. The immunogenicity of the entire antibody is then
determined using lymphocytes prepared from human HLA donors from each of the 20
HLA haplotypes.
Various immunoassays can be used for screening to identify antibodies having
the desired specificity for the polypeptides of this invention. Numerous protocols for
competitive binding or immunoradiometric assays using either polyclonal or
monoclonal antibodies with established specificity are well known in the art. Such
assays typically involve the measurement of complex ion between an
antigen and its specific antibody (e.g. , antigen/antibody complex formation). A twosite
, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two
non-interfering es on the polypeptides or peptides of this invention can be used
as well as a itive binding assay.
Antibodies can be conjugated to a solid support (e.g. , beads, , slides or
wells formed from materials such as latex or polystyrene) in accordance with known
techniques. dies can likewise be conjugated to detectable groups such as
radiolabels (e.g. , 35 S, 125 I, 131 I), enzyme labels (e.g. , adish peroxidase, alkaline
phosphatase), and fluorescence labels (e.g. , fluorescein) in accordance with known
techniques. Determination of the formation of an antibody/antigen complex in the
methods of this invention can be by detection of, for example, precipitation,
agglutination, flocculation, radioactivity, color development or , fluorescence,
luminescence, etc. , as is well known in the art.
In various embodiments, the antibody of this invention is an antibody or a
fragment thereof (e.g. , a monoclonal antibody) that specifically binds to IAP. In some
embodiments, the antibody of this invention is an antibody or a fragment thereof (e.g. ,
a monoclonal dy) that specifically binds to SHPS-1.
In one embodiment, the antibody is a monoclonal antibody produced by
hybridoma cell line NPG-1 (ATCC Deposit No. PTA-13161; ted August 17,
2012). In a further embodiment, the antibody is a monoclonal dy or a fragment
thereof that competes for binding to the same epitope specifically bound by the
monoclonal antibody produced by hybridoma cell line NPG-1 (ATCC t No.
PTA-13161; deposited August 17, 2012). In another embodiment, the antibody is a
monoclonal dy or a fragment f that specifically binds to the same e
specifically bound by the monoclonal antibody produced by hybridoma cell line
NPG-1 (ATCC Deposit No. PTA-13161; deposited August 17, 2012). In certain
embodiments, the monoclonal antibody or a fragment thereof is a ic antibody
or a humanized antibody. In additional embodiments, the chimeric or humanized
antibody comprises at least a portion of NPG-1 (ATCC Deposit No. PTA-13161;
ted August 17, 2012). As used herein, a “portion” of a CDR is defined as one
or more of the three loops from each of the light and heavy chain that make up the
CDRs (e.g., from 1-6 of the CDRs) or one or more portions of a loop comprising,
consisting essentially of, or consisting of at least three contiguous amino acids. For
e, the chimeric or humanized antibody may se l, 2, 3, 4, 5, or 6 CDR
loops, portions of 1, 2, 3, 4, 5, or 6 CDR loops, or a mixture thereofi.
B. Protein/peptide antagonists and other antagonists.
The amino terminal 1g domain of IAP and the extracellular 1g variable domain
of SHPS—l are sufficient for their physical interaction, and these regions may serve as
protein or peptide antagonists of IAP to SHPS‘-l binding. Thus, a further aspect of the
t invention is an active agent that is a protein or peptide comprising, consisting
of, or consisting essentially of the SHPS-l binding domain of IAP (e.g., an IAP
fragment; the amino terminal Ig domain of IAP). c examples include, but are
not limited to, a polypeptide consisting of amino acids 1 to 140 of mouse IAP; a
polypeptide consisting of amino acids 1 to 135 of mouse IAP; a polypeptide
consisting of amino acids 5 to 135 of mouse IAP; a polypeptide consisting of amino
acids 5 to 95 of mouse IAP; a polypeptide consisting of amino acids 19 to 95 of
mouse IAP; a ptide consisting of amino acids 1 to 140 of mouse IAP; a
polypeptide ting of amino acids 1 to 135 of rat IAP; eptide consisting of
amino acids 5 to 135 of rat IAP; a peptide consisting of amino acids 5 to 95 of rat
IAP; a polypeptide consisting of amino acids 19 to 95 of rat IAP; a peptide consisting
ofamino acids 1 to 10, 1 to 15, 1 to 20, l to 25, 1 to 30, l to 35,1 to 40, l to 50, l to
60, 1 to 70, 1 to 80, 1 to 90, 1 to 100, 1 to 110, 1 to 120, l to 130, 1 to 135 and/or 1 to
140 of human IAP; a peptide consisting of amino acids 5 to 15, 5 to 20, 5 to 25, 5 to
, 5 to 35, 5 to 40, 5 to 45, 5 to 50, 5 to 60, 5 to 70, 5 to 80, 5 to 95, 5 to 100, 5 to
110, 5 to 120, and/or 5 to 135 of human IAP; a peptide consisting of 10 to 20, 10 to
, 10 to 35, 10 to 40, 10 to 45, 10 to 50, 10 to 60, 10 to 70, 10 to 80, 10 to 95, 10 to
100, 10 to 110, 10 to 120, and/or 10 to 135 of human IAP; a peptide consisting of
amino acids 19 to 30, 19 to 35, 19 to 40, 19 to 45, 19 to 50, 19 to 60, 19 to 70, 19 to
80, 19 to 95, 19 to 100, 19 to 110, 19 to 120, and/or 19 to 135 ofhuman IAP, and a
peptide consisting of amino acids 30 to 50, 30 to 60, 30 to 70, 30 to 80, 30 to 90, 40 to
50, 40 to 60, 40 to 70, 40 to 80, 40 to 90, 40 to 100, 50 to 60, 50 to 70, 50 to 60, 60 to
70, 60 to 80, 70 to 80, 80 to 90, 70 to 90, 50 to 80, 50 to 90 and/or 50 to 100 ofhuman
IAP. Also ed herein are antibodies of this ion, which specifically bind
any of the IAP peptides and/or es Within any of the IAP peptides described
herein.
Mouse, human and rat IAP are all known as described above and numbering
herein refers to standard numbering assigned to amino acid residues in the full length
proteins. The numbering of the amino acids for. human IAP is based on the reference
amino acid ce of k® database Accession No. NP_942088 (incorporated
by reference herein) and is as follows, with the first amino acid numbered 1 and the
last amino acid numbered 305:
MWPLVAALLL GSACCGSAQL LFNKTKSVEF TFCNDTVVIP CFVTNMEAQN
TTEVYVKWKF KGRDIYTFDG ALNKSTVPTD FSSAKIEVSQ SLKM
DKSDAVSHTG NYTCEVTELT REGETIIELK YRVVSWFSP-N ENILIVIFPI
FAILLFWGQF GIKTLKYRSG GMDEKTIALL VAGLVITVIVIV GAILFVPG
EYSLKNATGL GLIVTSTGIL ILLHYYVFST AIGLTSFVIA ILVIQVIAYI
LAWGLSLCI AACIPMHGPL LISGLSILAL AQLLGLVYMK FVASNQKTIQ
PPRNN (SEQ ID N027).
In some embodiments, the IAP peptide can comprise, consist essentially of or
consist of a peptide having the amino acid sequence FVTNMEAQNTTEVYKWK (aa
42—59, SEQ ID NO:11), a peptide having the amino acid sequence ,
KWKFKGRDIYTFDGALNK (aa 57-74, SEQ ID NO:12), a peptide having the amino
acid sequence STVPTDFSSAKIEVSQLLKGD (aa 75—95, SEQ ID N0213), a peptide
having the amino acid ce YTFDGALNKSTVPTDFS (aa 66—92, SEQ ID
NO:14) and any combination thereof.
A still further aspect of the present invention is an active agent that is a protein
or peptide comprising, consisting of, or consisting ially of the IAP binding
domain of SHPS-l (e.g., an SHPS—l fragment; the extracellular Ig variable domain of
SHPS-l).
Specific es include, but are not limited to, a polypeptide ting of
amino acids 1 to 160 of mouse SHPS-l; a polypeptide consisting of amino acids 5 to
3O 150 of mouse SHPS—l; a polypeptide consisting of amino acids 29 to 150 of mouse
SHPS-l; a polypeptide consisting of amino acids 1 to 160 of rat SHPS-l; a
polypeptide consisting of amino acids 5 to 150 of rat SHPS-l; a polypeptide
consisting of amino acids 29 to 150 of rat SHPS—l; a e consisting of amino
acids 1 to 10, 1 to 15, l to 20, 1 to 25, 1 to 30, 1 to 35, 1 to 40, 1 to 50, 1 to 60,1,to
70, 1 to 80, l to 90, l to 100, l to 110, l to 120, l to 130, 1 to 135 and/or 1 to 140 of
human SHPS—l; a peptide consisting of amino acids 5 to 15, 5 to 20, 5 to 25, 5 to 30,
to 35, 5 to 40, 5 to 45, 5 to 50, 5 to 60, 5 to 70, 5 to 80, 5 to 95, 5 to 100, 5 to 110, 5
to 120, and/or 5 to 135 of human SHPS-l ; a e consisting of 10 to 20, 10 to 30,
to 35, 10 to 40, 10 to 45, 10 to 50, 10 to 60, 10 to 70, 10 to 80, 10 to 95, 10 to 100,
to 110, 10 to- 120, and/or 10 to '135 of human ; a peptide consisting of
amino acids 19 to 30, 19 to 35, 19 to 40, 19 to 45, 19 to 50, 19 to 60, 19 to 70, 19 to
80, 19 to 95, 19 to 100, 19 to 110, 19 to 120, and/or 19 to 135 of human SHPS—l, a
e consisting of amino acids 30 to 50, 30 to 60, 30 to 70, 30 to 80, 30 to 90, 40 to
50, 40 to 60, 40 to 70, 40 to 80, 40 to 90, 40 to 100, 50 to 60, 50 to 70, 50 to 80, 50 to
90 and/or 50 to 100 of human SHPS-l, and a peptide consisting of amino acids 100 to
120, 100 to 130, 100 to 140, 100 to 150, 120 to 140, 120 to 130, 120 to 150, 130 to
140 and/or 130 to 150 of human . Also provided herein are antibodies of this
invention, which specifically bind any of the SHPS-l es and/or epitopes within
any ofthe SHPS—l peptides described herein.
Mouse, human and rat SHPS—l are all known as described above and
numbering herein refers to standard numbering assigned to amino acid residues in the
full length proteins. The ing of the amino acids for human SHPS-l is based
on the reference amino acid sequence of GenBank® database Accession No.
BAA12974 (incorporated by reference herein) and is as follows, with the first amino
acid numbered 1 and the last amino acid numbered 503:
MEPAGPAPGR LGPLLCLLLA ASCAWSGVAG EEELQVIQPD KSVSVAAGES
AILHCTVTSL IPVGPIQWFR ELIY NQKEGHFPRV TTVSESTKRE
NMDFSISISN GTYY CVKFRKGSPD TEFKSGAGTE LSVRAKPSAP
VVSGPAARAT PQHTVSFTCE SHGFSPRDIT LKWFKNGNEL VDPV
GESVSYSIHS TAKVVLTRED VHSQVICEVA HVTLQGDPLR GTANLSETIR
VPPTLEVTQQ PVRAENQVNV TCQVRKFYPQ RLQLTWLENG NVSRTETAST
VTENKDGTYN VVMSWLLVNVS AHRDDVKLTC QVEHDGQPAV
SKSHDLKVSA HPKEQGSNTA AENTGSNERN IYIVVGVVCT LLVALLMAAL .
YLVRIRQKKA TRLH EPEKNAREIT QDTNDITYAD LNLPKGKKPA
PQAAEPNNHT EYASIQTSPQ PASEDTLTYA DLDMVHLNRT PKQPAPKPEP
SFSEYASVQV PRK (SEQ ID NO:15).
In some embodiments, the SHPS—l peptide can comprise, consist essentially of
or consist of a peptide having the amino acid sequence RELIYNQKEGHFPRVTTVS
2012/052384
(aa76—93, SEQ ID NO:16), a peptide having the amino acid sequence
VTSLIPVGPIQWFRG (aa57-71, SEQ ID NO:17), a peptide having the amino acid
sequence VKFRKGSP (aa 122—129, SEQ ID NO:l8) and any combination thereof.
IAP and SHPS-l fragments that may serve as active agents include analogs
thereof. An "analog" is a chemical compound. similar in structure to a first compound,
and having either a similar or opposite physiologic action as the first compound.‘ With
particular nce to the present invention, peptide analogs are those compounds
which, while not having the amino acid sequences of the corresponding protein or
peptide, are capable of antagonizing IAP to SHPS-l binding. Such analogs may be
peptide or non—peptide analogs, including but not limited to nucleic acid analogs, as
described in further detail below.
In n or peptide molecules which interact with a receptor (e.g., on IAP or
SHPS—l), the interaction between the protein or peptide and the receptor generally takes
place at surface—accessible sites in a stable three-dimensional molecule. By arranging
the critical binding site residues in an appropriate conformation, peptides analogs which
mimic the essential surface features of the peptides bed herein may be generated
and synthesized in ance with known techniques. Methods for determining peptide
three-dimensional structure and analogs thereto are known, and are sometimes ed
to as nal drug design ques". See,.e.g., US. Patent No. 4,833,092 to Geysen;
US. Patent No. 4,859,765 to Nestor; US. Patent No. 4,853,871 to iano; US.
Patent No. 4,863,857 to k; (applicants specifically intend that the sures of all
US. Patent references cited herein be incorporated by reference herein in their entirety).
See also p, Science 247, 28029 (1990); Rossmann, Nature 333, 392 (1988); Weis
et al., Nature 333, 426 (1988); James et al., Science 260, 1937 (1993) (development of
benzodiazepine peptidomimetic nds based on the structure and function of
. tetrapeptide s).
In general, those skilled in the art will appreciate that minor deletions or
substitutions maybe made to the amino acid sequences of proteins or peptides of the
present invention without unduly adversely affecting the activity thereof. Thus, peptides
containing such ons or substitutions are a further aspect of the present invention. In
peptides containing substitutions or replacements of amino acids, one or more amino
acids of a peptide ce may be replaced by one or more other amino acids wherein
such replacement does not affect the function of that sequence. Such changes can be
guided by known similarities between amino acids in physical features such as charge
density, hydrophobicity/hydrophilicity, size and configuration, so that amino acids are
substituted with other amino acids having essentially the same onal properties. For
e: Ala may be replaced with Val or Ser; Val may be replaced with Ala, Leu, Met,
or Ile, preferably Ala or Leu; Leu may be replaced with Ala, Val or Ile, ably Val or
Ile; Gly may be replaced with Pro or Cys, preferably Pro; Pro may be replaced with Gly,
Cys, Ser, or Met, preferably Gly, Cys, or Ser; Cys may be replaced with Gly, Pro, Ser, or
Met, preferably Pro or Met; Met may be replaced with Pro or Cys, preferably Cys; His
may be replaced with Phe or Gln, preferably Phe; Phe may be ed with His, Tyr, or
Trp, preferably His or Tyr; Tyr may be ed with His, Phe or Trp, preferably Phe or
Trp; Trp may be replaced with Phe or Tyr, preferably Tyr; Asn may be replaced with
Gln or Ser, ably Gln; Gln may be ed with His, Lys, Glu, Asn, or Ser,
preferably Asn or Ser; Ser may be replaced with Gln, Thr, Pro, Cys or Ala; Thr maybe
replaced with Gln or Ser, preferably Ser; Lys may be replaced with Gln or Arg; Arg may
be replaced with Lys, Asp or Glu, preferably Lys or Asp; Asp may be replaced with Lys,
Arg, or Glu, preferably Arg or Glu; and Glu may be replaced with Arg or Asp,
preferably Asp. Once made, changes can be routinely screened to determine their effects
on function with enzymes.
Non-peptide mimetics of the proteins or peptides of the present invention (i.e.,
non-peptide IAP to SHPS—l binding antagonists) are also an aspect of this ion.
Non-protein mimetics may be generated in accordance with known techniques such as
using computer graphic modeling to design non—peptide, organic molecules able to
antagonize IAP to SHPS—l binding. See, e.g., Knight, BIO/Technology 8:105 (1990);
Itzstein et al Nature 3632418 (1993) (peptidomirnetic inhibitors of influenza virus
enzyme, sialidase). Itzstein et al. Nature 3632418 (1993), modeled the crystal structure
of the sialidase receptor protein using data from x-ray crystallography s and
developed an inhibitor that would attachto active sites of the model; the use of nuclear
magnetic resonance (NMR) data for modeling is also known in the art and such
techniques may be utilized in ng out the instant ion. See also Lam et al.
Science 2632380 (1994) regarding the rational design of ilable nonpeptide cyclic
ureas that function as HIV protease inhibitors. Lam et al. used information fiom x—ray
crystal structure studies of HIV protease inhibitor complexes to design nonpeptide
inhibitors.
Analogs or antagonists may also be developed by utilizing high—throughput
screening of compound ies, as discussed in further detail below. Note that such
compound libraries may be fully random ies, or libraries generated and/or selected
based upon the information based upon the antibody active agents, IAP fragment active
agents, or SHPS-l nt active agents as described above.
Antagonists or analogs of the foregoing that may be used to carry out the
invention may also be developed by generating a library of molecules, selecting for
those molecules which act as antagonists, and identifying and amplifying the selected
antagonists. See, e.g., Kohl et al. Science 26021934 (1993) (synthesis and screening of
eptides for inhibitors of farnesyl protein transferase, to inhibit ras oncoprotein
dependent cell transformation). Eldred et al. (J. Med Chem. 3723882 (1994)) describe
nonpeptide antagonists that mimic the Arg—Gly-Asp sequence. Likewise, Ku et al. (J.
Med Chem. 38:9 (1995)) r illustrate the synthesis of a series of such compounds.
ques for constructing and screening atorial libraries of oligomeric
biomolecules to identify those that specifically bind to a given receptor protein are
known. Suitable oligomers include peptides, oligonucleotides, carbohydrates,
nonoligonucleotides (e.g., phosphorothioate oligonucleotides; see Chem. and
Engineering News, page 20, Feb. 7, 1994) and nonpeptide polymers (see, e.g.,
"peptoids" of Simon et al. Proc. Natl. Acad. Sci. USA 89:9367 ). See also US.
Pat. No. 5,270,170 to Schatz; Scott and Smith, Science 249:386-390 ; Devlin et
al. Science 249:404406 (1990); Edgington, BIO/Technology 112285 (1993). Peptide
libraries may be sized on solid supports, or expressed on the surface of
bacteriophage Viruses (phage display libraries). Known screening s may be
used by those skilled in the art to screen combinatorial libraries to fy
antagonists. Techniques are known in the art for screening synthesized molecules to
select- those with the desired activity, and for labeling the members of the library so
that selected active les may be identified. See, e.g., Brenner and Lerner, Proc.
Natl. Acad. Sci. USA 8925381 (1992) (use of genetic tag to label molecules in a
combinatorial library); PCT US93/06948 to Berger et al., (use of recombinant cell
transformed with Viral ctivating element to screen for potential antiviral
molecules able to inhibit initiation of viral transcription); Simon etal. Proc. Natl.
Acad. Sci. USA 89:9367 (1992) (generation and screening of "peptoids," oligomeric
N—substituted es, to identify ligands for biological receptors); US. Pat. No.
,283,173 to Fields et a1. (use of cally altered Saccharomyces cerevisiae to
screen peptides for interactions).
As used herein, "combinatorial library" refers to a collection of diverse
oligomeric biomolecules of ing sequence, which can be screened simultaneously
for activity as a ligand for a particular target. Combinatorial libraries may also be
referred to as "shape libraries," i.e., a tion of randomized polymers which are
potential ligands. The shape of a molecule refers to those features of a molecule that
govern its interactions with other molecules, including Van ,der Waals, hydrophobic,
electrostatic and dynamic. Screening procedures that may be used in conjunction with
such libraries are discussed in greater detail below.
C. Formulations and administration.
For administration, the active agent of this ion (e.g., an antibody or
antigen binding nt thereof) will lly be mixed, prior to administration,
with a non-toxic, pharmaceutically‘ able carrier substance (e.g. normal saline or
ate—buffered saline), and Will be stered using any medically appropriate
procedure, e.g., parenteral administration (e. g., injection) such as .by intravenous or
intra-arterial injection. In some embodiments, administration can be by injection into
the eye (e. g., intraocular, intraretinal and/or intravisceral injection). In some
embodiments, administration can be by injection directly into the site of treatment,
e.g., directly into a tumor. In some embodiments the active agent of this ion
can be linked or conjugated to a carrier (e.g., polyethylene glycol) to alter the half-life
or other properties of the active agent.
The active agents described above may be formulated for administration in a
pharmaceutical carrier in accordance with known techniques. See, e.g., Remington,
The Science And Practice of Pharmacy (9th Ed. 1995). In the manufacture of a
pharmaceutical formulation according to the invention, the active compound
(including the physiologically able salts thereof) is typically admixed with,
inter alia, an acceptable carrier. The carrier must, of course, be acceptable in the
sense of being compatible with any other ingredients in the formulation and must not
be deleterious to the patient. The carrier may be a liquid and is preferably formulated
with the compound as a unit-dose ation which may contain from 0.01 or 0.5%
to 95% or 99% by weight of the active compound.
Formulations of the-present invention suitable for parenteral administration
comprise sterile s and ueous injection solutions of the active compound,
which preparations are preferably isotonic with the blood of the intended recipient.
These preparations may contain anti—oxidants, buffers, bacteriostats and solutes which
render the formulation isotonic with the blood of the intended ent.
The active agents may be administered by any medically appropriate
procedure, e.g., normal intravenous or intra-arterial administration. In certain cases,
direct stration to an atherosclerotic vessel may be desired.
Active agents may be provided in lyophylized form in a sterile aseptic
container or may be provided in a pharmaceutical formulation in combination with a
pharmaceutically acceptable carrier, such as sterile pyrogen—free water or sterile
pyrogen—free physiological saline solution.
Dosage of the active agent will depend, among other things, on the condition
of the subject, the particular category or type of disorder or cancer being d, the
route of stration, the nature of the therapeutic agent employed, and the
sensitivity of the tumor to the particular therapeutic agent. For example, the. dosage
range can be from about 0.02 to about 5000 micrograms per kilogram subject body
weight. The specific dosage of the antibody or antigenic fragment thereof of this
invention is not critical, as long as it is effective to result in some beneficial effect in
some individuals within an affected tion. In some ments, the dosage
may be as low as about 0.02, 0.05, 0.1, 0.5, l, 5, 10, 20 or 50 micrograms per
am subject body weight, or lower, and as high as about 60, 75, 90, 100, 250,
500, 1000, 2000, 3000, 4000 or 5000 micrograms per kilogram subject body weight,
or even higher.
The. active agents of the present invention may optionally be stered in
conjunction with other, different, cytotoxic agents such as chemotherapeutic or
antineoplastic nds or radiation therapy useful in the treatment of the disorders
or conditions described herein (e.g., chemotherapeutics or antineoplastic compounds).
The other compounds may be stered concurrently. As used herein, the word
“concurrently” means sufficiently close in time to produce a combined effect (that is,
concurrently may be simultaneously, or it may be two or more administrations
occurring before or after each other) As used herein, thephrase "radiation therapy"
es, but is not limited to, x—rays or gamma rays which are delivered from either
an externally applied source such as a beam or by implantation of small radioactive
sources. Examples of other suitable chemotherapeutic agents which may be
rently administered with active agents as described herein include, but are not
limited to, Alkylating agents (including, without limitation, nitrogen mustards,
ethylenimine derivatives, alkyl sulfonates, oureas and triazenes): Uracil
mustard, Chlormethine, hosphamide (CytoxanTM), lfosfamide, Melphalan,
Chlorambucil, Pipobroman, Triethylene-melamine, Triethylenethiophosphoramine,
Busulfan, Carrnustine, Lomustine, Streptozocin, azine, and Temozolomide;
Antimetabolites ding, without limitation, folic acid antagonists, dine
analogs, purine analogs and adenosine deaminase inhibitors): Methotrexate, 5—
Fluorouracil, idine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine
phosphate, Pentostatine, and abine; Natural products and their derivatives (for
example, Vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and
epipodophyllotoxins): Vinblastine, Vincristine, Vindesine, BleOmycin, Dactinomycin,
Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Ara—C, paclitaxel (paclitaxel is
commercially available as ,Taxol®), mycin, o—formycin, Mitomycin—C,
L—Asparaginase, lnterferons ially lFN—a), Etoposide, and Teniposide; Other
anti—proliferative cytotoxic agents are navelbene, CPT-ll, azole, letrazole,
capecitabine, reloxafine, cyclophosphamide, ifosamide, and droloxafine.
Additional roliferative cytotoxic agents include, but are not limited to,
melphalan, hexamethyl melamine, pa, cytarabin, idatrexate, trimetrexate,
dacarbazine, L-asparaginase, camptothecin, topotecan, bicalutamide, flutamide,
leuprolide, pyridobenzoindole tives, interferons, and interleukins. Preferred
classes of antiproliferative cytotoxic agents are the EGFR inhibitors, Her—2 inhibitors,
CDK inhibitors, and Herceptin® (trastuzumab). (see, e.g., US Patent No. 6,537,988;
US Patent No. 6,420,377). Such compounds may be given in accordance with
techniques currently known for the administration thereof.
D. Screening procedures. ,
As noted above, the present invention provides screening procedures which may
be utilized alone or in combination with information on' the various active agents
described above to generate still additional active agents.
For example, active agents may also be developed by generating a library of
molecules, selecting for these molecules which act as ligands for a specified target, and
identifying and amplifying the selected ligands, as described herein.
Nucleic acid molecules may also act as ligands for receptor proteins. See, e.g.,
Edgington, BIO/Technology 11:285 (1993). US. Patent No. 5,270,163 to Gold and
Tuerk describes a method for identifying nucleic acid ligands for a given target molecule
by selecting from a library of RNA molecules with randomized sequences those
molecules that bind cally to the target molecule. A method for the in vitro
selection of RNA les logically cross-reactive with a specific peptide is
disclosed in Tsai, Kenan and Keene, Proc. Natl. Acad. Sci. USA 89:8864 (1992) and
Tsai and Keene, J. Immunology 150:1137 . In the , an rum raised
against a peptide is used to select RNA molecules from a library of RNA molecules;
selected RNA molecules and the e compete for dy binding, indicating that
the RNA epitope functions as a specific inhibitor of the antibody-antigen interaction.
As noted above, potential active agents or candidate compounds as described can
be readily screened for activity in (i) ting cellular activation by Insulin—like
Growth Factor-I (for example, ting cell growth by lGF—l), (ii) treating cancers
or tumors (as described above), and/or (iii) treating atherosclerosis (as described
above) and/or diabetic neuropathy and/or retinopathy and/or any other undesirable
er characterized by IGF-l induced cell proliferatidn. The method comprises the
steps of: (a) adding or contacting a test compound to an in vitro system comprising
the SHPS-l protein and the IAP protein (this term ing binding fragments
thereof sufficient to bind to the other); then (b) determining whether the test
compound is an nist of IAP to SHPS-l binding; and then (0) identifying the test
compound as active or potentially active in (i) inhibiting cellular activation by Insulin- .
like Growth Factor -1, (ii) treating cancers or tumors, and/or (iii) treating
atherosclerosis (or other disorder characterized by IGF-l induced cell proliferation)
when the test compound is an antagonist of IAP to SHPS-l binding. The in vitro
system may be in any suitable format, such as cells that express both the SHPS—l
protein and the IAP protein. In the alternative, the in vitro system may be a cell—free
systems, such as an aqueous preparation of SHPS-l and IAP, or the binding fragments
f. The contacting, determining and identifying steps may be are carried out in
any suitable manner, such as manually, semi-automated, or by a high throughput
screening apparatus. The determining step may be carried out by any suitable
technique, such as by precipitation, by labeling one of the fragments with a detectable
group such as a radioactive group, etc., all of which may be carried out in accordance
with procedures well known to those skilled in the art.
The present invention is explained in greater detail in the following non—
limiting Examples, in which the following abbreviations are used: Dulbecco’s
modified medium (DMEM—H), Fetal bovine serum (FBS), insulin—like growth factor—I
2012/052384
), IGF-l receptor (IGF—lR), immunoglobulin (lg), integrin associated protein
(IAP), serum free medium (SFM), smooth muscle cells (SMCS), Src homology 2
domain ning protein tyrosine phosphatase substrate 1 (SHPS-l), src homology 2
containing protein tyrosine phosphatase —2 (SHP-2).
EXAMPLE 1 ‘
The association between-integrin associated protein and SHPS-l
regulates IGF-l receptor signaling in vascular smooth muscle cells
Insulin—like growth factor—I (IGF—l) is a potent ator of smooth muscle
cell (SMC) migration and proliferation (Jones et al. Proc Natl Acad Sci USA 93:2482-
7 (1996)). There is increasing evidence to show that the ability of IGF-1 to initiate
intracellular signaling is regulated not only by its association with its own
transmembrane or but also by other transmembrane proteins such as the ocV133
integrin (B. Zheng and D. Clemmons Proc Natl Acad Sci USA 95:11217—22 (1998);
L. Maile and D. Clemmons J Biol Chem 277:8955—60 (2002)), integrin associated
n (IAP (L. Maile et al. J Biol Chem 277:1800-5 (2002))) and Src homology 2
domain ning protein tyrosine phosphatase substrate-1 (SHPS-l) (Maile and
Clemrnons, . ,
SHPS—l was identified as a tyrosine phosphorylated protein that binds to SHP—
2 in v-SRC transformed fibroblasts (T. Noguchi et al. J Biol Chem 271:27652—8
(1996)) and in n» stimulated Chinese hamster ovary cells (Y. a et a1. Mol
Cell Biol 16:6887-99 ). The cytoplasmic region of SHPS—l contains 2
immunoreceptor tyrosine based inhibitory motifs (A. Kharitonenkov et al. Nature
386:181—6 (1997)) that are orylated in response to various mitogenic stimuli
(see, e.g., M. Stofega et al. J Biol Chem 273:7112—7 ) and integrin mediated
cell attachment (see, e.g., T. Takada et al. J Biol Chem 273:9234—42 (1998)). This
phosphorylation generates binding sites for the recruitment and activation of Src
homology 2 domain tyrosine phosphatase (SHP-2) that in turn dephosphorylates
SHPS-l.
In stably attached smooth muscle cells (SMCs) SHP-2 is localized to a site
close to the cell membrane from where it is transferred to the SHPS-l following IGF—
1 stimulated SHPS—l phosphorylation (L. Maile and D. Clemmons J Biol Chem
277:8955—60 (2002)). This recruitment of SHP-2 is followed by the
dephosphorylation of SHPS-l and the transfer of SHP—2 to the IGF-lR where it
subsequently dephosphorylates this substrate. The importance of SHPS-l
phosphorylation in regulating IGF—lR dephosphorylation is demonstrated in cells
expressing a truncated form of SHPS-l in which the SHP-2 binding sites have been
deleted. In these cells transfer of SHP—2 to both SHPS—l and the IGF-IR is blocked
and sustained phosphorylation of both molecules is evident.
IAP was first identified by its ability to associate with ocVB3 (E. Brown et al. J
Cell Biol 111:2785—94 (1990)) and to increase the affinity of the integrin for its
ligands (E. Brown et al., J Cell Biol 111:2785—94 (1990)). IAP consists of a N—
terminal (extracellular) Ig variable type domain followed by five membrane spanning
hydrophobic helices and a cytoplasmic tail (C. Rosales et al. J l 149:2759-64
(1992); D. Cooper et al. Proc Natl Acad Sci USA 8—82 (1995)).
IAP has been shown to bind to SHPS-l (P. Jiang et al. J Biol Chem 274:559-
62 (1999); P. Oldenborg et al. Science 51—4 (2000); M. rt et al. Blood
94:3633—43 (1999); E. Vernon-Wilson et al., Eur JImmunol 30:2130-2137 (2000); H.
Yoshida et a1. JImmunol 13-20 ; I. Babic et al., JImmunol 164:3652-8
(2000)). The amino terminal Ig domain of IAP and the extracellular Ig variable
domain of SHPS—l are sufficient for their physical interaction. The effect of IAP
binding to SHPS—l 'on growth factor stimulated SHPS—l phosphorylation and SHP—2
recruitment has not been reported. The aim of these studies was to determine the
effect of IAP association with SHPS-l on IGF-l stimulated SHPS—l phosphorylation
and subsequent SHP—2 tment and to study how this alters IGF~1R dependent
SMC actions.
Experimental procedures.
Human IGF-l was obtained from Genentech (South San Francisco, CA,
USA); nyl difluoride membrane (IMMOBILON PTM) was purchased from
ore Corporation (Bedford, MA, USA). Autoradiographic film was obtained
from Eastman Kodak (Rochester, NY, USA). Fetal Bovine Serum, Dulbecco’s
modified medium, penicillin and streptomycin were purchased from Life
Technologies, (Grand , NY, USA). The IGF-lR [3 chain antibody and the
monoclonal phosphotyrosine dy (PY99) were purchased from Santa Cruz
(Santa Cruz, CA, USA). The polyclonal SHP—2 and SHPS—l antibodies were
purchased from Transduction Laboratories (Lexington, KY, USA). The monoclonal
antibody against IAP, B6H12, was purified from a B cell hybrid purchased from the
American Type e Collection (ATCC) and the anti FLAG onal antibody
was purchased from Sigma Chemical Company (St Louis, MO, USA). The antibody
against the dual phosphorylated (active) form of 4 MAP kinase (MAPK) and
the antibody against total p42/p44 MAPK protein were purchased from Cell Signaling
Technology (Beverley, MA, .USA); All other reagents were purchased from Sigma
Chemical Company (St Louis, MO, USA) unless otherwise stated.
Porcine aortic SMCs (pSMCs) were isolated as previously described (A.
Gockerman et a1. Endocrinology 136:4168-73 (1995)) and maintained in Dulbecco’s
modified medium supplemented with glucose (4.5 gin/liter), penicillin (100 units/ml),
streptomycin (100 ug/ml) (DMEM—H) and 10 % Fetal Bovine serum (PBS) in 10cm
tissue culture plates (Falcon Laboratory, Franklin Lakes, NJ). The cells were used
between passage 5 and 16.
Generation of sion Vectors
ength e IAP with a C-terminal FLAG epitope (IAPfl). Full-
length porcine IAP was cloned by RT-PCR from a cDNA library that had been
derived from pSMCs that had been isolated as previously described (A. Gockerman et
a1. Endocrinology 136:4168—73 (1995)). The 5’ primer sequence 5’
ATGTGGCCCTGGTGGTC (SEQ ID N021) corresponded to nucleotides 121—139 of
the porcine sequence. The 3’ primer sequence was complementary to nucleotides
1005-1030 with the addition of bases encoding the FLAG sequence (underlined) and a
stop codon. The sequence was:
’ TCATTTGTCGTCGTCGTCTTTGTAGTCGGTTGTATAGTCT 3’ (SEQ ID
NO:2).
Following cing, the cDNA was cloned into the pcDNA V5 his 3.1
vector (Invitrogen, Carlsbad, CA, USA).
IAP with tion of extracellular domain at residue 135 and
containing a inal FLAG epitope to). The pcDNA V5 his 3.1 vector
containing the IAPfl cDNA sequence was ized and the mutant form of IAP was
generated using PCR with a 5’ oligonucleotide encoding bases 527—556 (5’
TCTCCAAATGAAAAATCCTCATTGTTATT 3’) (SEQ ID NO:3) and the same 3’
oligonucleotide that was used to generate the IAPfl. The PCR product was cloned
into pcDNA V5 his 3.1.
WO 32948
IAP in which cysteine 33 and 261 are substituted with serine residues
containing a C-terminal FLAG epitope (IAPc—s). The IAPfl cDNA was subcloned
in a pRcRSV expression vector and it was used as a template to perform single
stranded nesis to incorporate the two substitutions. The pRcRSV vector
ns a in derivative (G418) resistance gene and a bacteriophage origin of
replication (Fl) gene that permits directsingle stranded mutagenesis of the cDNA.
Two oligonucleotides encoding the base substitutions were used. They were: C33S:
complementary to nucleotides 5 except for a base substitution to encode a
serine (underlined) 5’ GTAACAGTTGTATTGfiAACGGTGAATTCTA 3’ (SEQ
ID NO:4) and C2618: complementary to nucleotides 888-918 except for the base
substitution to encode the serine residue (underlined):
’ CCATGCACTGGGGTAQAQTCTGAGACGCAG (SEQ ID NO:5).
Following sequencing the DNA constructs were ned into pMEP4
expression vector (Invitrogen, Carlsbad, CA, USA).
Transfection of pSMCs. Cells that had been grown to 70 % ncy were
transfected with one of three IAP cDNA constructs as previously described (24).
Hygromycin resistant pSMCs were selected and maintained in DMEM-H ning
% FBS and 100 ug/ml hygromycin as described previously (Y. Imai et al., J Clin
Invest 100, 2596—605 (1997)). Expression of protein levels was assessed by preparing
whole cell lysates and visualizing FLAG protein expression by immunoblotting as
described herein. Transfected pSMCs that were obtained from two ections
performed independently were used in subsequent experiments and results obtained
were consistent between the two groups of cells.
Cell lysis. Cells were plated at a density of 5 x 105 in a 10 cm dishes (Falcon
# 3003) and then grown to 90 % confluency (approximately 5 x 106 cells). Cells were
incubated overnight in serum free medium with 0.5 % bovine serum albumin (SFM)
and then pretreated with either the monoclonal anti IAP antibody (B6H12) or an
irrelevant control monoclonal antibody for 2 hours (4 ug/ml) when required and then
treated with either 100 ng/ml IGF—l. or 10 ng/ml PDGF for the appropriate length of
time prior to lysis in ice—cold lysis buffer: 50mM Tris HCl (pH 7.5), 150mM NaCl,
1% NP40, 0.25% sodium deoxycholate, 1mM EGTA plus 1mM sodium
anadate, 1mM sodium fluoride, 1mM PMSF, 1 iile pepstatin A, l ug/ml
leupeptin, 1 ug/ml aprotinin. The s were clarified by centrifugation at 14,000 x
g for 10 minutes.
Immunoprecipitation. Cell lysates were incubated overnight at 4°C with the .
‘ appropriate antibody (IGF-lR, SHPS-l or B6H12 using a 1:500 dilution). Immune
complexes were then precipitated by adding protein A sepharose and incubating for a
further 2 hours at 4°C. The samples were then centrifuged at 14,000 x g for 10
minutes and the pellets washed 4 times with lysis buffer. The pellets were
resuspended in 45 ul of reducing or non-reducing Laemmeli buffer, boiled for 5
s and the proteins were separated by SDS—PAGE, 8% gel.
Assessment of p42/p44 MAP kinase activation. pSMCS were plated at 1 x
106 cells/well in six well plates DMEM—H with 0.5 % FBS and incubated at 37°C for
48 hours. Plates were then rinsed and incubated for a r 2 hours in fresh DMEM—
H with 0.5% FBS. Cells were thenincubated in SFM with or without 4 ug/ml of
B6H12 or vant control onal antibody for 2 hours prior to exposure to
IGF-l (100 ng/ml) for 20 minutes. Cells were then lysed with 200 pl of Laemelli
buffer and the proteins in 40 ul of cell lysate were then separated by SDS-PAGE (8%
gel). The activation of p42/44 MAPK was determined by immunoblotting with an
antibody specific for the dual phosphorylated (threonine202 and ne204) protein (at
a dilution of 1:1000) as described herein. To control for differences in protein levels,
an equal volume of cell lysate from each sample was loaded on an additional 8% gel.
Following separation and transfer, total p42/p44 protein levels were ined using
a polyclona1p42/p44 MAPK dy (at a dilution of 1:1000).
Western immunoblotting. Following SDS-PAGE the proteins were
transferred to Immobilon P membranes. The membranes were blocked in 1% BSA in
Tris—buffered saline with 0.1% Tween (TBST) for 2 hours at room temperature and
then incubated with one of six y antibodies (IGF-lR, SHP-2, SHPS—l, PY99,
B6H12 or FLAG, 1:500 dilution) overnight at 4°C and washed three times in TBST.
Binding of the peroxidase labeled secondary antibody was ized using enhanced
chemiluminescence following the manufacturer’s instructions (Pierce, Rockford IL,
USA) and the immune complexes were detected by exposure to autoradiographic film
or using the GeneGnome CCD imaging system (Syngene Cambridge, UK Ltd).
Chemiluminescent images ed were scanned using a DuoScan T1200
(AGFA ls, Belgium) and band ities of the scanned images were analyzed
using NIH Image, n 1.61. The Student’s t test was used to compare differences
between treatments. The results that are shown are representative of at least three
separate experiments.
Cell wounding and migration assay. Cells were plated in six-well plates and
grown to confluency over seven days with one medium change. Wounding was
performed as usly described (J. Jones et al. Proc Natl Acad Sci U S A 93: 2482—
7 (1996)). Briefly, a razor blade was used to scrape an area of cells leaving a denuded
area and a sharp visible wound line. Six 1 mm areas along the wound edge were
selected and recorded for each treatment. The wounded monolayers were then
incubated with SFM (plus 0.2% FBS) with or Without 100 ng/ml IGF—l or PDGF (10
ng/ml). The cells were then fixed and stained (Diff Quick, Dade Behring, Inc.,
Newark, DE) and the number of cells migrating into the wound area was counted. At
least five of the previously selected 1 mm areas at the edge of the wound were
counted for each data point.
Assessment of cell proliferation. Cells were plated at 5000 cells/cm2 on 24
well plates in DMEM-H with 2% FBS and allowed to attach and spread for 24 hours
before changing medium to DMEM—H plus 0.2% human platelet poor plasma.-
Following a further 24-hour incubation, cells were pre—incubated in the presence or
absence of B6H12 or an irrelevant control onal antibody (4 ug/ml) for 2 hours
prior to the addition of IGF-I (100 ng/ml). Each treatment was set up in triplicate.
Cells were then incubated for 48 hours and final cell number in each well determined.
The Student’s t test was used to compare differences between treatments. The results
that are shown represent the mean (iSEM) from three separate ments.
Results
IAP associates with SHPS-l in stably attached pSMCs via its extracellular
domain. Figure 1A shows that in stably attached quiescent SMCs there is detectable
association between IAP and SHPS—l as determined by co-immunoprecipitation
experiments using both anti IAP and anti SHPS—l dies for immunoprecipitation.
In order to investigate the role of IAP ation with SHPS—l in IGF—lR
signaling two experimental models were developed in which the association between
IAP and SHPS—l was ted. . The first approach was to use an anti-IAP
monoclonal antibody, B6H12, to ere with the binding of the two proteins.
Figure 1B shows that ing incubation of ent pSMCs with the anti IAP
monoclonal antibody (B6H12) the interaction between IAP and SHPS—l is reduced (a ,
75 i 7.5 % reduction (mean i S.E.M n = 3)). Preincubation with an irrelevant control
monoclonal antibody has no effect on the association between the two proteins.
The binding between IAP and SHPS-l specifically requires an intact disulfide
bond in IAP between cysteine 33 in the extracellular domain and cysteine 261 within
the putative transmembrane domain (R. Rebres et al., J Biol Chem 276:7672-80
- (2001)) If this bond is disrupted by mutagenesis, the ction of IAP with «V133 is
preserved but binding to SHPS-l is eliminated. Two mutant forms of IAP were .
generated and expressed in which the association between IAP and SHPS-l would be
expected to be disrupted. Figure 1C (top panel) shows the level of expression of
three forms of IAP that were used in subsequent experiments. These ed a) the
FLAG tagged mutant form of IAP in which the complete extracellular domain has
been deleted at amino acid residue 135 (IAPcyto), b) the FLAG tagged mutant form
of IAP in which the two cysteine residues 33 and 261 had been substituted with
s (IAPc-s) and c) the FLAG tagged full length IAP (IAPfl).
A representative ment shown in Figure 1C (lower panels) shows that
disruption of the extracellular domain of IAP alters its ability to associate with SHPS—
1. Expression of IAPcyto results in a 88 i 6.4 % (mean i SEM n=3) reduction in IAP
association With SHPS-l ed with association in cells expressing IAPfl. Since
truncation of the extracellular domain of IAP also disrupts its association with ocVB3
the SHPS—l/IAP interaction was analyzed in cells sing the IAPc—s mutation. In
cells expressing IAPc—s there is an 81 i 4.5 % (mean i SEM n=3) reduction in IAP
association with SHPS—l compared with cells expressing IAPfl. The control
immunoblots show that similar levels of SHPS-l were precipitated.
Blocking IAP—SHPS-l association inhibits IGF-l stimulated SHPS-l
2'5 phosphorylation and SHP-2 recruitment. To determine the functional
consequences of loss of physical association between IAP and SHPS—l, s were
conducted to examine SHPS-l phosphorylation in response to IGF—l in wild type cells
pretreated with the anti IAP monoclonal antibody B6H12. A representative
experiment is shown in Figure 2A and it can be seen that in contrast to the 4.1 i 0.9
(mean i SEM n = 3) fold se in SHPS—l phosphorylation in response to IGF-l in
controls, cells pretreated with B6H12 show a significant decrease (0.93 i 0.12 (mean
i SEM n = 3 p <0.05) in the IGF—l stimulated increase in SHPS—l phosphorylation.
In cells preincubated with an vant control monoclonal antibody IGF-l stimulated
SHPS-l phosphorylation did not differ significantly from control cells. As can also
been seen in Figure 2A this reduction in SHPS—l phosphorylation in the presence of
B6H12 is associated with a significant decrease in lGF-l stimulated tment of
SHP-Z to SHPS-l (a 1.8 i- 1._l fold increase in SHP-2 association in the presence of
B6H12 ed with a 14 i 1.5 fold se in control cells (mean i SEM n = 3 p<
0.05). Again there was no significant effect on IGF—l stimulated recruitment of SHP—
2 to SHPS—l in cells ubated with an irrelevant control monoclonal antibody.
The extracellular domain of IAP is required for IGF-l ated SHPS—l
phosphorylation and SHP—2 recruitment. In order to confirm the previous
observation that suggested that blocking IAP binding to SHPS—l ted IGF—l
stimulated SHPS—l phosphorylation, the ability of IGF-1 to stimulate SHPS—l
phoshorylation in cells expressing the mutant forms of IAP was compared with cells
expressing wild type IAP. The results from a entative experiment are shown in
Figure 2B and it can be seen that in contrast to the 3.6 i 0.8 (mean i SEM n = 3)
increase in SHPS-l phosphorylation in response to IGF-l in cells expressing IAPfl, in
cells expressing the IAPcyto mutant or IAPc—s mutant no significant increase in
SHPS-l phosphorylation in se to IGF-l can be detected.
Consistent with the results obtained using B6H12, the lack of SHPS—l
phosphorylation observed in the cells sing the mutant forms of IAP is
associated with an inhibition in SHP—2 recruitment to SHPS—l' in response to IGF—l
(Figure 2B).
Since SHPS—l has been shown to be phosphorylated in response to several
growth factors, studies were done to investigate the specificity of the requirement of
IAP binding to SHPS—l. Figure 2C shows that PDGF induces a marked increase in
SHPS—l phosphorylation following 5 minutes exposure in cells expressing IAPfl.
However, in contrast to IGF—l, PDGF also stimulated SHPS—l phosphorylation in the
IAPc-s cells.
The association between the extracellular domain of IAP and SHPS—l
tes the duration of IGF—lR phosphorylation Via its modulation of SHP—2
recruitment. Phosphorylation of SHPS-l is requiredfor SHP-2 transfer to the IGF-lR
and thereby regulates the duration of IGF-lR phosphorylation (T. Noguchi et al. J
Biol Chem 271:27652-8 (1996)); therefore studies were carried out to examine IGF—
1R recruitment of SHP-2 and the duration of lGF-lR phosphorylation in cells pre
treated with B6H12 and cells expressing the mutant forms of IAP. In control cells,
IGF-l stimulates a 3.3 i 0.4 (mean i SEM n = 3) fold increase in SHP-2 recruitment
to the IGF-l receptor following 10 minutes ent with lGF—l. However in cells
pretreated with B6H12 tment of SHP-2 to the IGF-lR there is no cant
increase seen in SHP—Z recruitment to the IGF—lR (Figure 3A). Consistent with
previous results (L. Maile and D. Clemmons, J Biol Chem 277:8955—60 (2002)) the
recruitment of SHP—Z to the lGF-lR precedes a reduction in receptor phosphorylation
ed following 20 minutes IGF-l stimulation. However, in cells ubated
with B6H12 consistent with the lack of SHP—2 recruitment no reduction in IGF-lR
phosphorylation is detectable at the 20—minute time point. To confirm that the lack of
SHP—2 recruitment to the IGF-lR in the cells pretreated with B6H12 was due to the
specific disruption between lAP/SHPS—l IGF—IR phosphorylation -was examined in
cells expressing IAPc—s. Figure 3B shows that in these cells there is no increase in
the recruitment of SHP—2 to the lGF-lR in response to lGF-l and again this is
associated with is a decrease in the amount of IGF-lR dephosphorylation ed
following 20 minutes stimulation with IGF—l in cells expressing full length IAP.
IGF—l stimulated MAPK ty is inhibited following disruption of SHP-
2 transfer. Previous studies have shown that sion of an inactive form of SHP-
2 results in an inhibition of IGF—1 stimulated MAPK (S. Manes et a1. M01 Cell Biol
4:3125—35 (1999)). To e the consequence of the lack of SHP-2 transfer
following the disruption of IAP—SHPS-l binding, the tion of MAPK in response
to IGF—l in the presence of B6H12 was analyzed.
Figure 4A shows that 10 minutes of IGF—1 treatment stimulates a marked
increase in the activation of MAPK as determined by the assessment of the dual
phosphorylation of p42/p44 MAPK (70 i 5 % S.E.M n = 4). r, when cells
were preincubated with B6H12, lGF—l was unable to stimulate a sustained increase in
p42/p44 MAPK phosphorylation. MAPK is required for IGF—l to stimulate cell
proliferation.
To examine the consequence of the disruption in PS-l association on
IGF-l action in SMCs, the effect of B6H12 on IGF-l stimulated cell proliferation was
determined. Figure 4B shows that IGF-l stimulates a 2.2 i 0.2 (mean 1 SEM n = 3)
fold increase in cell proliferation. However when cells are incubated with B6H12
there is a significant reduction in IGF—l stimulated cell proliferation (1.03 i 0.01
WO 32948
mean i SEM n = 3 p < 0.05 compared with cells incubated in the absence of B6H12.
The inhibition in cell proliferation is consistent with the inhibition of IGF-1
stimulated MAPK activation.
Disruption of the IAP interaction with SHPS-l inhibits IGF-l stimulated
cell migration. Preincubation of pSMCs with B6H12 ts IGF-l stimulated
migration in part by ng the ction between IAP and OLVB3 (L. Maile et al. J
Biol Chem 277:1800—5 (2002)). To determine Whether at least part- of the effect of
B6H12 was also due to the inhibition of IAP binding to SHPS—l cell ion in
response to IGF-l was compared in cells expressing IAPfl and the IAPc—s mutant. In
Figure 5 it can be seen that IGF—l stimulated a significant increase in pSMC
migration in cells expressing IAPfl. However, in cells expressing the IAPc-s mutant
IGF-l stimulated migration is significantly reduced. In st, PDGF stimulated
cell migration of the IAPc—s cells is not significantly different to cells expressing full
length IAP.
sion
The role of SHPS-l in intracellular signaling has largely been attributed to the
recruitment of SHP-2 to the orylated tyrosines contained within ITIM motifs in
the cytoplasmic tail of SHPS—l and the subsequent activation of SHP—2 phosphatase
activity (L. Maile et al. J Biol Chem 277:1800-5 (2002); T. Takada et al. J Biol Chem
273:9234—42 (1998); J. Timms et al., Curr Biol 9:927-30 (1999)). The requirement
for transfer of activated SHP—2 to downstream signaling les for growth factors
such as IGF-l to stimulate their physiologic actions has been strongly suggested by
studies showing that expression of dominant negative forms of SHP—2 result in failure
to properly te growth factor stimulated increases in MAP kinase (T. Noguchi et
al. Mol Cell Biol 14:6674-82 (1994); K. Milarski and A. Saltiel J Biol Chem
269:21239-43 (1994); S. Xiao et al. J Biol Chem 269:21244—8 (1994); K. Yamauchi
et al. Proc Natl Acad Sci 92:664—8 ; G. Pronk et al. Mol Cell Biol 14:1575—81
(1994); T. Sasaoka et al. JBiol Chem 269:10734—8 (1994)) and PI—3 kinase (C. Wu et
a1. Oncogene 20:6018—25 (2001); S. Ugi et a1. JBiol Chem 271:12595—602 (1996); S.
Zhang et a1. Mol Cell Biol 22:4062-72 (2002)) as well as failure to recruit SHP-Z to
downstream signaling molecules. For IGF-l it was specifically shown that expression
of a dominant negative SHP-2 mutant resulted in a failure to activate MAP kinase or
W0 032948
cell migration in response to IGF-l (S. Manes et al. M01 Cell Biol 4:3125-35 (1999)).
The s from this study have demonstrated that the interaction between the IAP
and SHPS-l is a key regulator of IGF-1 ing since these data have shown that the
interaction is necessary for SHP-2 recruitment and transfer. Disruption of the
interaction between the two proteins using two independent approaches resulted in a
loss of SHP-2 recruitment to SHPS-l and subsequent transfer to the lGF-IR which
was reflected in prolonged IGF-lR phosphorylation. The consequence of lack of
SHP-2 recruitment and transfer was evident in the inability of IGF-I to stimulate
MAPK activation and subsequently cell proliferation or cell migration.
The interaction between SHPS-l and IAP was first ted by experiments
that demonstrated that anti IAP monoclonal antibodies blocked the attachment of
cerebellar s, erthyrocytes and thymocytes to a substratum containing P84 (a
brain homolog of SHPS—l) ( P. Jiang et al. J Biol Chem 274:559-62 (1999); M.
Seiffert et al., Blood 94:3633-43 ). That this ction might play a role in
o-cell attachment was substantiated in experiments which demonstrated that the
expression of the extracellular domain of SIRPoc in SIRP negative cells supported
adhesion of primary hematopoietic cells and this interaction was again inhibited by
anti IAP monoclonal antibodies (E. Vernon-Wilson et al. Eur J Immzmol 30:2130-
2137 (2000)).
Cell adhesion molecules mediating either cell attachment to the extracellular
, for example integrins and cell to cell adhesion molecules, for example
cadherins, are important not only for cell attachment but also for the regulation of cell
proliferation, survival and differentiation. The regulation of growth factor signaling
by integrin receptors has been well documented. It has been previously reported that
ligand occupancy of ocVB3 is necessary for IGF-l stimulated receptor signaling and a
similar cooperative relationship between mVB3 and the PDGF or has also been
described (S. Miyamoto et al. J. Cell. Biol. 135:16633-1642 (1996)). IGF-l has been
shown to be a regulator of various homophilic cell to cell on molecules.
Guvakova et al. reported that the lGF-lR colocalizes with erin and ses
cell adhesion of MCF-7 cells by increasing expression of ZO-l which binds to E-
in and stabilizes its interaction with the cytoskeleton (L. Mauro et al. J. Biol.
Chem. 276: 3982-39897). Conversely, it has also been shown in human colonic
tumor cells that lGF-l via its ability to stimulate E—cadherin phosphorylation results in
reduced membrane levels of E~cadherin and associated reduction in cell
adhesion. lGF-l has also been reported to downregulate T-cadherin expression again
this was associated with a decrease in cell on. Despite the apparent role of cell
to cell adhesion ors in regulating cell function there is little data regarding their
ability to regulate growth factor- action.- It has been shown previously that the
interaction of neuronal cell adhesion molecules with the fibroblast growth factor
receptor leads to receptor activation by autophosphorylation. VEGF has been shown _
to result in an increase in CEACAM expression and at least some of the effects of
VEGF are mediated through CEACAM-l. The s from these experiments
demonstrate that the interaction of the cell tocell on molecules IAP and SHPS-
1, in addition to mediating cell adhesion, also play an important regulatory role in
growth factor signaling. Given the importance of cell to cell adhesion molecules in
regulating cell function it is able to conclude that the regulation of growth
factor signaling by cell to cell adhesion molecules is a general mechanism for
regulating growth factor action. PDGF signaling was not affected by disruption of the
IAP-SHPS—l interaction.
Since PDGF could still stimulate SHPS-l orylation in the absence of
IAP binding to SHPS-l this suggests that PDGF and lGF-l may stimulate SHPS-l
phosphorylation via two different kinases. SHPS-l has been shown to be
phosphorylated directly by the insulin receptor kinase (Y. Fujioka et al., Mol Cell Biol
16, 6887—99 (1996)). Given the homology between the ne kinase domains in the
insulin and lGF—lR (e. g., 84 %) it is possible that SHPS-l is also a direct substrate for
the IGF-IR kinase. IAP binding to SHPS-l could modulate this process by localizing
SHPS-l in close ity to the or kinase or alternatively IAP binding to
SHPS—l could alter the conformation of the SHPS—l cytoplasmic domain making its
tyrosines accessible to the lGF—lR kinase.
By virtue of its ability to stimulate SMC ion and proliferation, IGF-l is
likely to be an ant contributor to the development of atherosclerosis (J. Jones et
al. Proc Natl Acad Sci USA 2—7 (1996)); M. Khorsandi ’et a1. nvest.
90 :1926-1931 (1992); B. Cerek et al. Circ.Res. 66 :1755-1760 (1990); P. Hayry et al.,
FASEB J. 9 :1336—1344 (1995)). In mice in which IGF-l was overexpressed in SMCs
there was an increase in the rate of neointimal formation after carotid injury that
ed to have resulted from increased SMC proliferation and migration. The
effect was apparent despite equivalent levels of serum lGF—l in plasma compared
with control animals suggesting a paracrine effect of locally produced IGF—l (B. Zhu
et al. Endocrinology 142:3598-3666 (2001)). Given the apparent role of IGF-1 in the
development of atherosclerosis and the effect of this interaction on IGF—l signaling it
is likely that this system may play a role in the development of atherosclerosis and
disruption of the interaction may represent a novel therapeutic strategy to specifically
t IGF—l action. Current approaches to target IGF—l signaling have focused on
blocking the activity of the receptor itself using antibodies or peptides. Disrupting
cell to cell adhesion molecule interactions that specifically inhibit growth factor
signaling offers a novel therapeutic strategy.
EXAMPLE 2
Treatment of diabetic retinopathy with a onal antibody (NPG—l) that
ts IAP binding to SHPS-l
In vivo measurement of vascular bility
Rats were injected with Nembutal (80 mg/kg) (Southern Anesthesia). Once
deep anesthesia had been ed, warmed Evans blue (45 mg/kg) (Fisher Scientific)
solution was injected via the tail vein. After 2 hrs a lethal dose of anesthetic (100
mg/kg) was administered. The chest Cavity was opened and a needle inserted into the
left ventricle. The right atrium was clipped and blood was centrifuged at 12,000 x g
for 5 min. The rats were perfused with 1% paraformaldehyde in e then the eyes
were removed and placed in PBS. The retinas were removed, lyophilized, and then
resuspended in formamide and incubated at 70°C. After 18 hrs the retina/formamide
was fuged at 13,000 x g for 10 min.
A standard curve was generated using serial dilutions of Evans Blue (30
mg/ul). The ance of the standard curve as well as each retina was measured
using a Nanodrop spectrophotometer (Thermo—Scientific) using an excitation and
emission wavelength of 620 and 740 nm, respectively. The amount of Evans Blue
permeation from each retina was calculated using this formula:
Evans Blue tug) / retina dry weight g g) ‘
Time-averaged Evans Blue concentration (ug) / plasma (ul) x circulation (h)
Diabetes induction protocol
Control (CON) rats received an injection of vehicle.
_ Streptozotocin (STZ)
was given by intraperitoneal injection (50 mg/kg; 100 ml). After 6 days rats with
blood e >350 mg/dl were denoted as‘having diabetes. The STZ treated group
was divided into two groups. At 20 days nj ection, the first group received an
injection of control, mouse IgG (5.0 mg/kg), every 72 hours for 30 days. The second
received an injection of rat anti IAP antibody NPG—l (5.0 mg/kg) every 72 hours for
days. The rats were weighed daily and if weight loss was apparent they received
insulin (4—8 units/kg).
Cell lysis, precipitation and immunoblotting
Lysates were prepared from endothelial cell monolayers that had been exposed
to various treatments. They were immunoprecipitated and immune complexes .were
separated by SDSrPAGE and transferred to Immobilon filters pore) prior to
blotting to visualize proteins. Antibodies used for immunoblotting were anti—
phosphotyrosine (PY99, Santa Cruz), anti-SHPS-l (BD Biosources) and anti-occludin
(Invitrogen).
In vitro permeability assay
Transwell inserts (24 well) were coated with collagen 10 ug/cm2 (BD
Biosciences) for 1 hr at 22°C. HUVECs were plated on the coated inserts at 5 X 104
cells/ml/insert in growth medium (15mM e). After 24 hrs, 500 pl of growth
medium was placed in the lower chambers. After 24 hrs, medium was changed to
SFM-199 (15mM glucose) containing IGF-l (50 ng/ml) plus anti IAP'antibody NPG-
1 (1 ug/ml). After 14 hrs, fluorescently labeled dextran was added (Sigma) (0.5
mg/ml). After 1 hr, medium was removed from the lower r and the amount of
FITC—dextran was measured in a fluorescence ing microplate reader (Fluor
Imager 595 Molecular Dynamics) (using excitation and emission wave lengths of 294
and 521 nm, respectively).
In vitro tube formation assay
Human umbilical vein endothelial cells (HUVECs)'were grown to confluence
and then d to SF M-199 ning IGF-l‘ (50 ng/ml), NPG—l (1 ug/ml) for 14
hr. They were trypsinized and resuspended in SF M-199 (15mM glucose) and then
plated on 24 well plates coated with 500 pl of growth factor d matrigel (BD
Sciences) (1.5 x 105 cells/ml/well). After 4 hours the plates were photographed at 10x
and the number of tubes/cm2 area in 6 random areas of each well was determined.
One tube is the area between two branch points (shown in Figure 7C as the area
between two “x” markers on the image).
Endothelial cell culture
Primary human unbillical vein endothelial cells (HUVECs) (Lonza,
Walkersville, MD, USA) were grown in M-199 (Life Technologies, Grand Island, ‘
NY, USA) plus EGM-2 elial Cell Growth Medium supplements (Lonza) .
containing 5 mmol/1 glucose. HUVECs were switched to growth medium containing
mmol/1 glucose for 3 days. Mannitol (10 mmol/l) was added to the medium
containing 5 mmol/1 glucose to control for the differencein osmolarity. Cultures were
quiesced for 14 h in serum—free M-l99 ning 5 or 1.5 mmol/1 e, and
d to IGF-l .(50 ng/ml; Genentech, San Francisco, CA, USA), with or without
the anti-IAP antibody, NPG-l (l ug/ml). The use of human cells was approved by
the University ofNorth Carolina Ethics tee.
Results
Two types of endothelial cells (rat and human) were used for the in vitro
assays. The monoclonal antibody NPG—l ed against amino acids 71 through‘80
of the human IAP protein (amino acid numbering according to reference sequence
provided herein) binds specifically to human IAP. Figure 6A shows a comparison
between control and NPG—l and es a direct demonstration that this dy can
disrupt IAP binding to SHPS-l. The cells were pr'e-incubated with NPG—l and then
SHPS-l was immunoprecipitated and the immunoprecipitate was immunoblotted for
IAP. e the disruption results in inhibition of IGF-l signaling one would expect
critical signal transduction elements that are activated in response to IGF-l tobe ,
inhibited. Figure 6B shows that She, which has to bind to SHE’S-l to be activated in ~
endothelial cells, does not bind normally if. the cells are pre—incubated with this
antibody. Most antibodies that react with IAP also disrupt IAP binding to aVB3.
Figure 6C shows that NPG—l is c in that it disrupts IAP binding to SHPS—l
without disrupting IAP binding to B3. This is important e disrupting IAP
binding to [33 could lead to side effects such as increased platelet aggregation. This is
an important distinguishing feature of this antibody. SHPS—l association with IAP
was determined in the aorta homogenates from control (Con), diabetic (D) and
diabetic rats treated with the anti-IAP antibody (R569) (D + AB) as shoWn in Figure
6D. The antibody was fully active in Vivo and inhibited IAP/SHPS-l association.
As a companion to this study, an experiment is shown wherein the ability of
human endothelial cells to form tubes in an in. vitro assay of ary formation that
occurs in vivo is demonstrated. Endothelial cell tube formationis shown in Figure
7C. Figure 7A shows cell permeability that is measured in vitro based on dextran
blue permeation. The endothelial cells grow in monolayer much as they do in blood
s and the ability of this dye to penetrate the monolayer is measured. As can be
seen from Figure 7A, IGF-l stimulates permeation and this is ted in the
presence of the IAP antibody. Figure 7B shows that the tight junction protein
occludin, which allows endothelial cells to form a bility barrier, is disrupted in
the presence of IGF-1; i,e., occludin leaves the junctional complex that is normally
fo'rmedand diffuses out into the cell. That is why there is a decrease in immunoblot
intensity of the occludin band. In the presence of the dy NPG—l , this effect of
IGF-1 is completely inhibited. In Figure 7C, in IGF—l treated cells tube formation
can be seen, wherein the capillary cells are joining each other with capillary tubes. In
the presence of the antibody NPG—l, this is completely disrupted as shown in the
lower two panels of Figure 7C and on the bar graph, where the number of tubes per
cm2 is shown.
Studies described in Figure 8 and Figure 9 were conducted in rat endothelial
cells. This is because the amino acid ce 71. through 80 of the IAP protein is not
ved across species. Because the amino acids 71-80 are different in rat IAP
(NKNSTTREQN, SEQ ID N028) as opposed to human IAP (ALNKSTVPTD, SEQ
ID N026), studies were conducted to show that this amino acid ce had the same
functional significance. Thiswas necessary because if the human antibody to IAP is
administered to rats in vivo it would not work not because this amino acid sequence is
not conserved across species therefore the human antibody would not be expected to
disrupt rat IAP binding to rat SHPS-l. Therefore an at IAP antibody was
ed by immunizing rabbits with an immunogen that was comprised of a 10
amino acid sequence from rat IAP that was homologous to the human IAP sequence
that was used to prepare the monoclonal antibody. As stated herein, this peptide was
conjugated to KLH and rabbits were immunized. The IgG was then purified from
rabbit serum using n A sepharose. This was the purified IgG that was injected
into the ratsto inhibit capillary permeability. This rat antibody was validated in the
same way the human dy was validated, to show that the rat antibody would
inhibit IAP/SHPS-l association in rat endothelial cells and that it would inhibit IGF—l
signaling. As shown in Figure 8A, the control antibody (Con) had no effect on
IAP/SHPS-l interaction whereas the anti—rat IAP antibody (AB) completely disrupted
their association. Figure 8B shows that following IGF-l stimulation there is ne
phosphorylation of SHPS—l, stimulation of AKT and MAPK activation and'that these
are inhibited in the presence of the rat anti-IAP antibody.
Figure 9 shows the results of an in vivo ment in which the same
antibody that disrupted SHPSl/IAP association in rat endothelial cells in vitro was
ed into rats in vivo. This experiment was conducted over a three week period.
The rats were made diabetic as described herein and then received injections of the
purified anti—rat antibody twice a week. Evans blue dye permeation out of the retinal
capillaries into the retina of the diabetic rats was then measured. As shown in Figure
9, there is a major increase in capillary bility in diabetic rats (hyperglycemic),
which is a rk of diabetic retinopathy. As also shown in Figure 9, injection of
the rat anti-IAP antibody inhibited this increase in permeability. ' ar
permeabilityis one of the first changes that occur in human diabetic retinopathy. This
rat model demonstrates Evans blue leakage, which is a standard assay for measuring
vascular permeability (see Kern “In vivo models of diabetic retinopathy”
Contemporary Diabetes 2:137-151 (2008; Bhatt and Addepalli uation of
diabetic retinopathy by enhanced inhibition of MMP—2 and MMP-9 using aspirin and
cline in streptozotocin—diabetic rats” Am. J Transl. Res 2(2):181—l89 (2010)).
Therefore it is known in the art as a surrogate animal model of these early changes
that occur in human diabetic retinopathy. This leakage of vessels is directly linked to
Visual loss since it can result in fluid accumulation around the macula and macular
damage is a known cause of severe visual loss in patients with diabetic retinopathy.
Furthermore factors such as vascular endothelial growth factor inhibitors that inhibit
this capillary leak have been shown to t other changes that occur in diabetic
retinopathy. In summary since the antibody directed against amino acids 71 through
80 of rat IAP (a region that is homologous to the same sequence in human IAP)
inhibits retinal capillary leak it is ed that it will be an effective treatment for
human diabetic retinopathy.
Rationale: Integrin associated protein, also known as IAP and CD 47, is a
transmembrane protein that functions as a self recognition n on cells. This
means that when it binds to a protein (termed SHPS—l) that is localized on
macrophage surfaces, these cells do not secrete cytokines that activate cell killing and
the target cells that express IAP remain viable. Many types of cells undergoing
normal sis fail to s IAP thus enabling this killing to take place
efficiently. Several types of cancer cells in contrast either express IAP abnormally or
do not proteolytically cleave the SHPS—l binding site from IAP and therefore are
resistant to ment by activated macrophages. It has been postulated that
disrupting IAP/SHPS—l association would lead to increased killing oftumor cells.
However, an amino acid ce within IAP that possesses enough heterogeneity to
be able to encode several types of different self recognition sequences has not been
fied. The studies of this invention have established that the region within amino
acids 71 to 80 contains this self recognition information and that it is involved in IAP
binding to SHPS-l. In contrast to other types of antibodies that have been developed
that disrupt the association of IAP/SHPS—l , the antibody of this invention targets this
sequence within amino acids 71—80, thereby directly» ering with self ition
thus resulting in tumor cell ment. Importantly the antibody of this ion
does not interrupt interactions between IAP and other cell surface proteins such as the
beta 3 subunit of the alphaVbeta3 integrin. This is important because these other
interactions mediate cell processes that are necessary for the maintenance of
logic functions of normal cells.
As the antibody of this invention is directed against this c site,
experiments will be done to establish that disruption of the binding of this site to
SHPS-l on tumor cells s in inhibition of cancer cell growth. These experiments
will be performed in two phases. In the first phase, the monoclonal antibody of this
invention or control IgG will be added to cancer cells (e.g. , breast, prostate, colon,
r, ovarian cancer cells, etc., as described herein) grown in culture under
standard conditions and stimulated to grow with 10% fetal calf serum. Additional
cultures would contain the growth factor insulin like growth factor I (IGF-I), since
IAP/SHPS-l association is known to be involved in IGF—I stimulated cell
proliferation. Increasing concentrations of dy between 0.05 and 5.0 ug/ml
would be added to cultures and cell proliferation measured 48 hours later by direct
counting. Control cultures will receive an equal concentration of IgG. IGF-I would
be used in a concentration of 50 ng/mL. If the antibody is successful in inhibiting the
proliferation of tumor cells then an in viva experiment will be undertaken. In this
experiment, immunocompromised mice will be injected with, 6g, 3 million tumor
cells/m1 subcutaneously. There will be, e. g., 12 mice/treatment. One group will
receive the active antibody at a concentration that will be determined from the results
of the in vitro ment. For example if an antibody concentration of 100 ng /ml
resulted in complete inhibition of cell growth, then to achieve that serum
concentration, 400 ug would be injected intraperitoneally into each mouse. All mice
in the active treatment group would receive the same concentration of antibody that
would be administered weekly for a period of six weeks to eight weeks. Control
animals would e an equal tration of mouse IgG. The animals in both
groups will be sacrificed and tumor volume and weight determined. Tumor
metastases will be determined by analyzing histologic sections of lung, liver, kidney
and brain. The tumor tissue will also be analyzed for the presence of intact IAP by
SDS polyacrylamide gel ophoresis and for IAP/SHPS-l' association by
immunoprecipitation of SHPS-l followed by immunoblotting for IAP. Further
analyses of activation of the kinases involved in cell proliferation such as AKT and
MAP kinase will also be undertaken using known techniques to determine their
activated forms. The results of this ment will establish that disrupting the
binding of this specific site on IAP to SHPS—l results in inhibition of tumor cell
proliferation.
The foregoing is illustrative of the present invention, and is not to be ued
as limiting thereof. The ion is defined by the following claims, with
equivalents of the claims to be included therein.
Claims (18)
1. A monoclonal antibody that specifically binds an epitope within amino acids 71-80 of the human IAP protein and is an antagonist of IAP to SHPS-1 binding.
2. The antibody of claim 1, coupled to a detectable group.
3. The antibody of claim 1 or claim 2, coupled to a therapeutic group.
4. The antibody of any one of claims 1 to 3, wherein the antibody does not disrupt IAP binding to a β3 protein.
5. A pharmaceutical ation sing the antibody of any one of claims 1 to 4 in a pharmaceutically acceptable carrier.
6. The antibody of claim 1, wherein the antibody is selected from the group consisting of (a) the monoclonal antibody produced by hybridoma NPG-1, and (b) a monoclonal antibody that competes for binding to the same e as the epitope bound by a monoclonal antibody ed by the hybridoma NPG-1.
7. The dy of claim 6, coupled to a detectable group.
8. The antibody of claim 6 or claim 7, coupled to a therapeutic group.
9. A pharmaceutical formulation comprising the antibody of any one of claims 6 to 8 in a pharmaceutically acceptable carrier.
10. The use of an antibody of any one of claims 1 to 4 in the production of a medicament for inhibiting IGF-1 actions in a subject in need f.
11. The use of an antibody of any one of claims 6 to 8 in the production of a medicament for inhibiting IGF-1 actions in a subject in need thereof.
12. The use of an antibody of any one of claims 1 to 4 or 6 to 8 in the production of a medicament for treating retinopathy in a subject.
13. The use of an dy of any one of claims 1 to 4 or 6 to 8 in the production of a medicament for treating atherosclerosis in a subject.
14. The use of an antibody of any one of claims 1 to 4 or 6 to 8 in the production of a medicament for treating nephropathy in a t.
15. The use of an antibody of any one of claims 1 to 4 or 6 to 8 in the production of a medicament for treating coronary artery disease in a subject.
16. The use of an antibody of any one of claims 1 to 4 or 6 to 8 in the production of a medicament for ng cancer in a subject.
17. An antibody according to claim 1 or claim 6, substantially as herein bed with reference to any one of the accompanying examples and/or figures thereof.
18. The use according to any one of claims 10 to 16, substantially as herein described with reference to any one of the accompanying examples and/or figures thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/219,276 | 2011-08-26 | ||
US13/219,276 US8613922B2 (en) | 2003-04-24 | 2011-08-26 | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
PCT/US2012/052384 WO2013032948A1 (en) | 2011-08-26 | 2012-08-24 | Method for inhibiting cellular activation by insulin-like growth factor-1 |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ621515A NZ621515A (en) | 2016-03-31 |
NZ621515B2 true NZ621515B2 (en) | 2016-07-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8613922B2 (en) | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) | |
US20230110249A1 (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
US20080160013A1 (en) | Method for inhibiting cellular activation by insulin-like growth factor-1 | |
EP1871807B1 (en) | Antibodies against cxcr4 and methods of use thereof | |
US9328155B2 (en) | Peptides for inducing antibodies to a non-functional P2X7 receptor | |
UA126657C2 (en) | Bcma and cd3 bispecific t cell engaging antibody constructs | |
US20100215640A1 (en) | Method for inhibiting cellular activation by insulin-like growth factor-1 | |
JP7198083B2 (en) | Enhanced depletion of target cells using CD47 blockade and immune co-stimulatory agonists | |
CN105518028A (en) | Novel dual-targeted protein specifically binding to DLL4 AND VEGf, and use thereof | |
EA024655B1 (en) | LIGAND BINDING TO MSRV-ENV (VARIANTS), ScFV AND Fab FRAGMENTS, ANTIBODY, METHOD OF PRODUCING THE SAME, PHARMACEUTICAL COMPOSITION, NUCLEIC ACIDS, VECTOR, HOST CELL, METHOD OF TREATMENT, ANTI-LIGAND AND METHOD OF DETECTION THEREOF, KIT AND USE THEREOF | |
US20120328604A1 (en) | Methods and compositions for treating and preventing disease associated with avb5 integrin | |
NZ621515B2 (en) | Method for inhibiting cellular activation by insulin-like growth factor-1 | |
US11046779B2 (en) | Antibody specifically binding to PAUF protein and use thereof | |
Barden et al. | Peptides for inducing antibodies to a non-functional P2X 7 receptor | |
Barden et al. | Antibodies for binding to non-functional P2X 7 receptors in trimeric form |